Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Cited by 267 Publications

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(3):536-548.e21

PubMed: 29961578 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 21(10):1163-71

PubMed: 26390243 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 158(5):989-99

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 471(7337):235-9

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )
Clin Epigenetics, 2019, 11(1):85

PubMed: 31142371 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656155

PubMed: 31423895 ( click the link to review the publication )

Epigenetics, 2019, 14(8):791-803

PubMed: 31088315 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz254

PubMed: 31691806 ( click the link to review the publication )

Pharmacol Res, 2019, 139:524-534

PubMed: 30366100 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

Bone, 2019, 125:112-121

PubMed: 31100533 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(13)

PubMed: 31269745 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

NMR Biomed, 2019, 32(2):e4044

PubMed: 30561869 ( click the link to review the publication )

Stem Cells Dev, 2019, 28(7):438-453

PubMed: 30667343 ( click the link to review the publication )

Chem Biol Interact, 2019, 306:54-61

PubMed: 30958996 ( click the link to review the publication )
Gene Ther, 2019, 26(3-4):75-85

PubMed: 30538307 ( click the link to review the publication )

Cancer Med, 2019, 8(14):6383-6392

PubMed: 31456359 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0218382

PubMed: 31206526 ( click the link to review the publication )

Exp Hematol, 2019, 72:60-71

PubMed: 30769020 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Alcohol, 2019, 78:79-87

PubMed: 30851364 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3579-3584

PubMed: 31262882 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Medicina (Kaunas), 2019, 55(2)

PubMed: 30700046 ( click the link to review the publication )

Cell Host Microbe, 2018, 24(5):689-702

PubMed: 30344003 ( click the link to review the publication )

Sci Adv, 2018, 4(9):eaar4666

PubMed: 30263952 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

Haematologica, 2018, 103(4):679-687

PubMed: 29305415 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):153

PubMed: 30012171 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )
J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):466

PubMed: 29695239 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):264-270

PubMed: 29115632 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):481-486

PubMed: 29505792 ( click the link to review the publication )

AAPS PharmSciTech, 2018, 19(2):634-647

PubMed: 28948528 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(1):47-54

PubMed: 27870832 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Haematologica, 2017, 102(4):736-745

PubMed: 27979926 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Oncogene, 2017, 36(34):4859-4874

PubMed: 28414307 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(20):3608-3622

PubMed: 28749535 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1485-1492

PubMed: 28498513 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

J Biol Chem, 2017, 292(12):5043-5054

PubMed: 28167529 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Pharm Res, 2017, 34(3):668-679

PubMed: 28101809 ( click the link to review the publication )

Cancer Med, 2017, 6(11):2673-2685

PubMed: 29024573 ( click the link to review the publication )
Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:88-95

PubMed: 28323055 ( click the link to review the publication )

Am J Surg, 2017, 213(4):645-651

PubMed: 28007318 ( click the link to review the publication )

Oncotarget, 2017, 9(1):512-523

PubMed: 29416632 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

CPT Pharmacometrics Syst Pharmacol, 2017, 6(11):756-764

PubMed: 29045072 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2290

PubMed: 28536458 ( click the link to review the publication )

Oncotarget, 2017, 8(45):78480-78495

PubMed: 29108243 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(28):45687-45697

PubMed: 28537899 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Drug Discov Today, 2016, 21(9):1553-1560

PubMed: 27371506 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1364-75

PubMed: 27196750 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(6):2076-92

PubMed: 27067055 ( click the link to review the publication )
Neuropharmacology, 2016, 107:111-121

PubMed: 26970016 ( click the link to review the publication )

Biochem Pharmacol, 2016, 102:130-140

PubMed: 26718586 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10131-47

PubMed: 27022024 ( click the link to review the publication )

Neurochem Int, 2016, 96:24-31

PubMed: 27103167 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2016, 311(5):H1139-H1149

PubMed: 27638876 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Anal Bioanal Chem, 2016, 408(13):3547-53

PubMed: 26968571 ( click the link to review the publication )

BMC Cancer, 2016, 16:667

PubMed: 27549189 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

Med Oncol, 2016, 33(2):11

PubMed: 26732474 ( click the link to review the publication )

Inflammation, 2016, 39(1):39-46

PubMed: 26228975 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0145985

PubMed: 26726879 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(3):692-9

PubMed: 26084206 ( click the link to review the publication )

Asian Pac J Trop Med, 2016, 9(6):572-6

PubMed: 27262069 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58142-58147

PubMed: 27494885 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Nat Commun, 2015, 6:7888

PubMed: 26223951 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )
EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:33

PubMed: 25888415 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1657

PubMed: 25695609 ( click the link to review the publication )

Circ Heart Fail, 2015, 8(6):1094-104

PubMed: 26371176 ( click the link to review the publication )

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

Neuropharmacology, 2015, 99:67-78

PubMed: 26188143 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochem Pharmacol, 2015, 94(2):79-90

PubMed: 25600908 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(7):975-85

PubMed: 25835755 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(3):1829-36

PubMed: 25492871 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )
BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):4291-4297

PubMed: 26095064 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Acta Neuropathol, 2014, 128(2):291-303

PubMed: 24839957 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

Oncogene, 2014, 33(25):3307-15

PubMed: 23995789 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2014, 14(1):112

PubMed: 25546354 ( click the link to review the publication )
Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Res, 2013, 73(8):2428-34

PubMed: 23382048 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )
Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 160(2):188-98

PubMed: 23167276 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

PLoS Comput Biol, 2013, 9(2):e1002887

PubMed: 23408876 ( click the link to review the publication )

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )

Front Pharmacol, 2013, 4:44

PubMed: 23596417 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )
J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )

Oncol Rep, 2012, 28(1):105-10

PubMed: 22484732 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )

Mol Med, 2011, 17(5-6):466-72

PubMed: 21424110 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )

BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )
Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	NYXMeJRJU2mwYYPlJGF{e2G7		NHe0bZoyKGh?	Mnr6SG1UVw>?	M4m3dIFvfGlvSFTBR\|Eh[WO2aY\peJkhf2m2aDDJR\|UxKG:oIECuNVEzKM7:TR?=	M4jXOFEyQTZyNEi5
Friend leukemic cell	M3fD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUS1NEDPxE1?	NXTSeWVXPzJiaB?=	M2T0N2ROW09?	Mm\lTWM2OD1yLkm5JO69VQ>?	M4TBelEzOTB7OUGz
K562	M1PZcmtqdmG\|ZTDBd5NigQ>?		M2rpV\|YhcA>?	NGrnPHdFVVOR	MkHkTY5pcWKrdHnvckBw\iCqdX3hckBpcXO2b37lJIRm[WOndInsZZNmKCivaYj0eZJmKG:oIFjERWMyKGGwZDDISGFEOilid3n0bEBKSzVyIH;mJFAvODFizszN	NH3vVZUyOjRzOUO4NC=>
HT1080	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYDOdoZ1PzJiaB?=	NFnoWoxFVVOR	NIDFPXJKSzVyPUKuOEDPxE1?	NIDkVY8yOjJ5MEG3OS=>
H1299	M3LsbGtqdmG\|ZTDBd5NigQ>?		NIP1SIwzOCCvaX6=	MVrEUXNQ	M17WcGlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBJTEGFIHXufplu\SC5aYToJGlEPTBib3[gNE4yQTRizszN	MXmxOFUzOTR{Mh?=
H1299	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlnrO\|IhcA>?	M2SyUWROW09?	Mk\OTWM2OD15LkK0JO69VQ>?	NWXQV2h4OTR3MkG0NlI>
HeLa	MmHWT4lv[XOnIFHzd4F6		NHfyWnU{OCCvaX6=		MYHJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCqaYP0c45mKGSnYXPleJlt[XOnIIfpeIghUUN3MDDv[kAxNjJ6IN88US=>	M3fY[\|E2PjB\|OUS5
LOX-IMVI	M3PQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1zRU\|Q5KGh?		NV;CUXRyUUN3ME2xMlMh\|ryP	NIH3fI0yPTdzNUS3NC=>
NCI-H226	M1e5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWPEOYFFPDhiaB?=		NHn2e\|dKSzVyPUKuOkDPxE1?	MXuxOVcyPTR5MB?=
RXF-631L	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M37zWVQ5KGh?		MnjmTWM2OD1{IN88US=>	NVvUfmI{OTV5MUW0O\|A>
SNB-78	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mm\jOFghcA>?		MWHJR\|UxRTF4IN88US=>	NUH3S\|A6OTV5MUW0O\|A>
St-4	NUDCZ2s5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnjIOFghcA>?		M4rHVWlEPTB;NT6yJO69VQ>?	NUHvW4o5OTV5MUW0O\|A>
ARP1	MlPhSpVv[3Srb36gRZN{[Xl?	MnjkNkDPxE1?	Mnz5OkBp		NFHwU5VKdmS3Y4Tpc44hd2ZiUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44>	NILKeZYyPDd\|NEiwOi=>
CEM	NF\Q[5JMcW6jc3WgRZN{[Xl?		MU[xJIg>	NFTqPINFVVOR	NYW4bHU2UW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlM{KM7:TR?=	NEO4UVYyPjR{MEC2OC=>
HCT15	MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1;oblQ5KGh?		Mn3hS2k2OD1yLkiyJO69VQ>?	NUD2UHVkOTZ5MkOyNlc>
NCI-H23	MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWTK[JJpPDhiaB?=		NH;hWlZIUTVyPUCuPVIh\|ryP	NGHNXFAyPjd{M{KyOy=>
GM15850	MoT5T4lv[XOnIFHzd4F6	NF;J[FIzNjVizszN	NYnpTJY2QTZiaB?=	MV7EUXNQ	NVLKdo5NUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NX:wXGJYOTZ7MkGzOlc>
GM15850	NYricXJxU2mwYYPlJGF{e2G7	NGKycWszNjVizszN	MXm5OkBp	MUXEUXNQ	NUOwTIVyUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFUh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M2PqblE3QTJzM{[3
GM15850	M{LLfWtqdmG\|ZTDBd5NigQ>?	Ml7mNk42KM7:TR?=	NUPhT415QTZiaB?=	MXfEUXNQ	MWTJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViMUKgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	Mo\PNVY6OjF\|Nke=
GM15850	M3Xw[GtqdmG\|ZTDBd5NigQ>?	NHf5dogzNjVizszN	NXHuWGNWQTZiaB?=	MYHEUXNQ	NXfiT4lEUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M1XpVlE3QTJzM{[3
GM15850	M{D4TWtqdmG\|ZTDBd5NigQ>?	MnK3Nk42KM7:TR?=	M2PSXlk3KGh?	NYq4WGF7TE2VTx?=	MV7Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViODDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?	MkHBNVY6OjF\|Nke=
GM15850	MWXLbY5ie2ViQYPzZZk>	MV:yMlUh\|ryP	M3[1dFk3KGh?	MlrqSG1UVw>?	MkPuTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEG2JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	NVT5eWp6OTZ7MkGzOlc>
U937	M4nyZWZ2dmO2aX;uJGF{e2G7	NInu[IM2KM7:TR?=	NUfDcWJTOjRiaB?=	M2fHZWROW09?	MofBR4VtdCCleXPs[UBienKnc4SgZpkh[WOldX31cIF1cW:wIHH0JHMwTzJxTTDwbIF{\Q>?	MlXuNVcxODR5MUi=
H661	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGW1VoU1QCCq		NGjtS\|FKSzVyPUGg{txO	MlvBNVcyPTdyMEm=
U937	NEKzbXpHfW6ldHnvckBCe3OjeR?=	MnryOUDPxE1?	NXvHNlhWOjRiaB?=	NVPM[mNoTE2VTx?=	NUDBTnJqUW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=>	M2D2WlE4PDR5N{Ww
U937	M1nPU2Z2dmO2aX;uJGF{e2G7	NXnyRZZvOSEQvF2=	NYLDT5U6OjRiaB?=	NX7mUXBQTE2VTx?=	NIHLNXlG\m[nY4Sgc44h[WyyaHGgeJVjfWyrbjDhZ4V1gWyjdHnvci=>	M{fZb\|E4PDR5N{Ww
RAW264.7	MVTGeY5kfGmxbjDBd5NigQ>?	NYjKUpJJOTBizszN	NFTYeowzPGh?	MXj3ZZRmeg>?	NWjzSFkyUW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCWTl\hcJBp[SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjd4IN88US=>	NInsXmwyPzR5N{WxPC=>
RAW264.7	MnLiSpVv[3Srb36gRZN{[Xl?	M{H4d\|ExKM7:TR?=	NVfaS4h{OjSq	NXzuNppPf2G2ZYK=	M{D5fmlvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhVk9icILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOS56ODFOwG0>	MlzhNVc1Pzd3MUi=
SC9	NU\MfFhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYC0PEBp		MYHJR\|UxRTBwNkC2JO69VQ>?	MW[xO\|UxPzJzOR?=
ST14A	MlHQSpVv[3Srb36gRZN{[Xl?	M3XXZVUhdk1?	M2Ozd\|czKGh?		M1u3bGlv[3KnYYPlJIlvKFKHU2SvUnJUTiCvUl7BJIV5eHKnc4Ppc44>	M{LSSVE4PTZ3OUmz
ST14A	M4rDXWZ2dmO2aX;uJGF{e2G7	NILvWVY2KG6P	MXG3NkBp		NIXZbmZKdmO{ZXHz[UBqdiCHMl[xJI1TVkFiZYjwdoV{e2mxbh?=	M2jaOVE4PTZ3OUmz
PANC1	M1;URWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;MfZMyKM7:TR?=			MUXJR\|UxRTBwNEWg{txO	NYjmZplUOTd3OEi3OFQ>
PANC1	NHXxfYNHfW6ldHnvckBCe3OjeR?=	NXz6fWVDOSEQvF2=	M37WdFI1KGh?		NX3YRYFnUW6lcnXhd4UhcW5icEKxW2FHOS:FSWCxJIdmdmViZYjwdoV{e2mxbh?=	NUThUnBPOTd3OEi3OFQ>
PANC1	MUXGeY5kfGmxbjDBd5NigQ>?	NWrFXpBIOSEQvF2=	M3iyRlI1KGh?		NFX3VolKdmO{ZXHz[UBqdiCyMkfrbZAyKGenbnWg[ZhxemW\|c3nvci=>	M{TKPFE4PTh6N{S0
PT45	NXu1SnV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTRizszN	MUmxO\|U5QDd2NB?=
ACHN	M1XtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4rDblIyKGh?		NVyyUo1iT0l3ME2wMlY2KM7:TR?=	MVyxO\|Y3OjZyNh?=
PC3	M1XCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXLhOnJSOjFiaB?=		NHKzZVdIUTVyPUCuO\|Eh\|ryP	MoHKNVc3PjJ4ME[=
A431	MWHDfZRwfG:6aXOgRZN{[Xl?		NXS3OWdNPzJiaB?=		M3fGc2lEPTB;ND6yJO69VQ>?	M1y2d\|E4PjlzN{[z
Cal27	M1;RbGN6fG:2b4jpZ{BCe3OjeR?=		NGHNUYM4OiCq		MmK5TWM2OD1\|LkKg{txO	NEfXc40yPzZ7MUe2Ny=>
CCRF-CEM	MmnCR5l1d3SxeHnjJGF{e2G7		MUm3NkBp		MmHUTWM2OD1yLkig{txO	NY\Ce4pDOTd4OUG3OlM>
EOL1	MWnDfZRwfG:6aXOgRZN{[Xl?		NUnBR3l{PzJiaB?=		MXfJR\|UxRTFizszN	M1i2eFE4PjlzN{[z
Hec-1-A	MY\DfZRwfG:6aXOgRZN{[Xl?		M{jMfFczKGh?		MlXCTWM2OD1zIN88US=>	M1q3blE4PjlzN{[z
HeLa	MmTyT4lv[XOnIFHzd4F6	MX6xNEDPxE1?	MXKzNEBucW5?	MnzBSG1UVw>?	Mkn2TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDISGFEOSC5aYToJGlEPTBib3[gNE4xOiEQvF2=	MY[xO\|Y6OTd4Mx?=
RKOp21	MUHDfZRwfG:6aXOgRZN{[Xl?		NV7FWVF[PzJiaB?=		NXrkdnhqUUN3ME2xMlc3KM7:TR?=	MWqxO\|Y6OTd4Mx?=
Saos2	NELEWYNEgXSxdH;4bYMhSXO\|YYm=		Mnr6O\|IhcA>?		NFntNllKSzVyPUKuN{DPxE1?	NVzpZ\|A2OTd4OUG3OlM>
SK-OV-3	NILJbWdEgXSxdH;4bYMhSXO\|YYm=		MorLO\|IhcA>?		NYnGXW1ZUUN3ME2yMlIh\|ryP	M3i4VVE4PjlzN{[z
U87MG	MlfqR5l1d3SxeHnjJGF{e2G7		Mn7mO\|IhcA>?		NX7kVJRLUUN3ME2xNUDPxE1?	NVnydHFIOTd4OUG3OlM>
NUGC3	M3LJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXWR44zPSEQvF2=	NUi1SpJNOjRiaB?=		NUGweHF5T0l3ME2yMlc6KM7:TR?=	NWXxdVdDOTd7MES4OFM>
CCD1059SK	NWjhNWxlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\tXW5YUUN3ME20N{42KM7:TR?=	NVzMWWNCOTh{NEe1OVQ>
HepG2	M4TBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1G0T2lEPTB;MD6wNFA3KM7:TR?=	MnLoNVgzPDd3NUS=
HT1080	M1v4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWf6Zmt3UUN3ME2wMlAxOjRizszN	NXLjZYQ5OTh{NEe1OVQ>
SKBR3	NVzXUIR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTBwODFOwG0>	MUWxPFI1PzV3NB?=
SNB78	NVHtRZp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\FR\|UxRTF4IN88US=>	M2\4SVE5OjR5NUW0
SQ20B	MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33TPWlEPTB;MzFOwG0>	M{[4UFE5OjR5NUW0
St4	NWja[ZZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37xeWVEPTB;NT6yJO69VQ>?	NIDB[2kyQDJ2N{W1OC=>
MCF7	MmjJSpVv[3Srb36gRZN{[Xl?	M4XHTlExKM7:TR?=	MnXMPEBp	Mo\DSG1UVw>?	MUTJcoR2[3Srb36gc4YhfHWkdXzpckBpgXCncnHj[ZR6dGG2aX;u	MYqxPFI3QTJ{Nh?=
HEK293	MlfvT4lv[XOnIFHzd4F6		MmS1NUBp	NV7scmV4TE2VTx?=	NITw[IJKdmirYnn0bY9vKG:oIFjERWMyKHerdHigTWM2OCCxZjCwMlA{KM7:TR?=	NH3yTWcyQDNyOEW2Ny=>
HEK293	MYrLbY5ie2ViQYPzZZk>		M2rjdFEhcA>?	NH7NbHdFVVOR	NEO3W4dKdmirYnn0bY9vKG:oIFjERWM{KHerdHigTWM2OCCxZjCwMlA2PyEQvF2=	MoXhNVg{ODh3NkO=
G401	MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mki0O\|IhcA>?	NX\pbZJNTE2VTx?=	MoHQTWM2OD1zIN88US=>	MVSxPFM4ODN5Mx?=
HeLa	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYjVdGxHPzJiaB?=	MVnEUXNQ	M2nFS2lEPTB;MD60OkDPxE1?	NW\oSG9IOTh\|N{CzO\|M>
Human renal epithelial cell	M1HZdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIex[\|k4OiCq	NV7iZXc5TE2VTx?=	NILldYpKSzVyPUG0JO69VQ>?	NWj2fWJWOTh\|N{CzO\|M>
U937	MWPGeY5kfGmxbjDBd5NigQ>?	NGHod282KM7:TR?=	MkXQNlQhcA>?		NV7jdI1bUW6mdXP0bY9vKG:oIHjpd5RwdmViSESgbJlx\XKjY3X0fYxifGmxbh?=	M1PuVlE5OzhzMkO4
U937	MYTGeY5kfGmxbjDBd5NigQ>?	MnvnOUDPxE1?	MXWyOEBp		NVnRdYg2UW6mdXP0bY9vKG:oIHHsdIhiKHS3YoXsbY4hcHmyZYLhZ4V1gWyjdHnvci=>	MV:xPFM5OTJ\|OB?=
U937	MljLSpVv[3Srb36gRZN{[Xl?	MV[1JO69VQ>?	NUThTWdTOjRiaB?=		MkjvTY5lfWO2aX;uJI9nKHB{MTDlfJBz\XO\|aX;u	NEfpSVkyQDN6MUKzPC=>
U937	NIHSWpNHfW6ldHnvckBCe3OjeR?=	NUXob3FrPSEQvF2=	M136XFI1KGh?		Mn;aTY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>?	NUDTTFJqOTh\|OEGyN\|g>
U937	M1fhXWZ2dmO2aX;uJGF{e2G7	MVe1JO69VQ>?	MoDRNlQhcA>?		M1PmeGlv\HWldHnvckBw\iCpcnHueYxw[3m2aXOg[Iln\mW{ZX70bYF1cW:w	NVe2Nm5SOTh\|OEGyN\|g>
U937	NXfHNlVrU2mwYYPlJGF{e2G7	M2nnS\|Uh\|ryP	Mk\rNlQhcA>?		NHzOV5lKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOx	MlPaNVg{QDF{M{i=
U937	NF;rfoNMcW6jc3WgRZN{[Xl?	MmnuOUDPxE1?	NFv4WlYzPCCq		NG\oZ3NKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO0	NYT1Z3Q1OTh\|OEGyN\|g>
HEK-TE	NXrkfVBFTnWwY4Tpc44hSXO\|YYm=	NUPu[pp[PSEQvF2=	NXj3ZVMzPmh?	M1;EUWROW09?	M{K4Umlv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36=	MlLFNVg1OzRzNES=
HPDE6c7	NUC2c2Z[S3m2b4TvfIlkKEG\|c3H5	NX;nOG9YPTBizszN	NXLVcoRDPzJiaB?=	MlnKSG1UVw>?	M1XGPWlEPTB;MT6zJO69VQ>?	M2DuPFE5PDl2NE[z
Human microvascular epithelial cell	Mnq3R5l1d3SxeHnjJGF{e2G7	MmC4OVAh\|ryP	MnfaO\|IhcA>?	NIC3e3FFVVOR	NVT2NlVjUUN3ME2xMlMh\|ryP	MVyxPFQ6PDR4Mx?=
Hup T3	Mo\OR5l1d3SxeHnjJGF{e2G7	NIniTXU2OCEQvF2=	M2DUc\|czcA>?	MVPEUXNQ	MX3JR\|UxRTBwODFOwG0>	M4fJUVE5PDl2NE[z
Mia Paca2	NGn3dlhEgXSxdH;4bYMhSXO\|YYm=	NUfXfYprPTBizszN	NV7T[YlTPzKq	NYfSRppZTE2VTx?=	MmD1TWM2OD1zLkGg{txO	Mn3TNVg1QTR2NkO=
Panc 04.03	NVWxNlhbS3m2b4TvfIlkKEG\|c3H5	MnLDOVAh\|ryP	MnnXO\|Jp	MUPEUXNQ	MmCzTWM2OD1zLkKg{txO	Ml3LNVg1QTR2NkO=
SU 86.86	NGTyZW1EgXSxdH;4bYMhSXO\|YYm=	M33ZU\|UxKM7:TR?=	MmrZO\|Jp	MUTEUXNQ	M1S4ZWlEPTB;MT6zJO69VQ>?	NH6wdYwyQDR7NES2Ny=>
HEK293	M2Lrc2tqdmG\|ZTDBd5NigQ>?		NV\k[lNiOyCq		NIq4N4NKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhFSUN4IHX4dJJme3Orb36ge4l1cCCLQ{WwJI9nKDBwMEG5JO69VQ>?	MlTwNVg2PTh4Nkm=
HeLa	MYnLbY5ie2ViQYPzZZk>		MVuyJIg>		M2PTe2lvcGmkaYTpc44hd2ZiboXjcIVieiCKRFHDJJdqfGhiSVO1NEBw\iByLkC4N{DPxE1?	NHLzToYyQDV3OE[2PS=>
RAW264.7	MXHGeY5kfGmxbjDBd5NigQ>?	NF30dFAzKM7:TR?=	MWqzMlUhcA>?	M1vn[2ROW09?	NHrmfJNCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCCSbHHzcY9lcXWvIH\hcINqeGG{dX2gbY5n\WO2ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO	NULDXW94OTh4NES5Olk>
NB4			M3zMcVQ5cA>?	NVOxcVlTTE2VTx?=	M3XnOGlEPTB;MD62JO69VQ>?	MVqxPFczOzN2OR?=
HEK293	MnH0SpVv[3Srb36gRZN{[Xl?	MmTxNVAh\|ryP	MlXUNlQhcA>?	NUT4bZVNTE2VTx?=	NHXjR3FC[3SrdnH0bY9vKG:oIH3veZNmKFewdEPhJJNq\26jbHnu[{BmgHC{ZYPz[YQ>	Mn20NVkxOjJ4N{W=
HCT116	Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYK3Nog>	NUnEXZJKTE2VTx?=	NGDzbllKSzVyPUCuN\|Eh\|ryP	MVSxPVA5PDJ7NB?=
HeLa	NUfQZ\|RWU2mwYYPlJGF{e2G7	NF3peHQzKM7:TR?=	MV[zNEBucW5?	MonTSG1UVw>?	MmDvTY5pcWKrdHnvckBw\iCKRFHDNkBqdiCqdX3hckBJ\UyjIHPlcIx{KHerdHigTWM2OCCxZjCwMlEh\|ryP	MmrpNVkxQDR{OUS=
IGROV1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXS3NkBp	NH;ncJRFVVOR	MlTZTWM2OD1{LkKg{txO	NEjndZQyQTB6NEK5OC=>
IGROV1	M2m0OmtqdmG\|ZTDBd5NigQ>?	MUS1JO69VQ>?	MonrNlQhcA>?	NIjCfmhFVVOR	MnPnTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KHB3MzDhZ4V1gWyjdHnvci=>	NF\yOZcyQTB6NEK5OC=>
IGROV1	MWPLbY5ie2ViQYPzZZk>	MVKxNEDPxE1?	M{Lvb\|QhcA>?	Mly5SG1UVw>?	MoLOTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUuUDRiYXPleJlt[XSrb36=	NGPIdYkyQTB6NEK5OC=>
IGROV1	Ml\zT4lv[XOnIFHzd4F6	NHzr[HkyOCEQvF2=	NGTqSJQ1KGh?	Mn7YSG1UVw>?	MVHJcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W\|c3XkJIF{KGGucHjhMZR2[nWuaX6gZYNmfHmuYYTpc44>	NV\ZfWt7OTlyOESyPVQ>
T24	NHrybZdMcW6jc3WgRZN{[Xl?		NUHSO5J2OyCq		NIHzWJlKdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKMzDhZ4V1gWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xNkDPxE1?	MXWxPVA5PDN7NR?=
T24	MnKzT4lv[XOnIFHzd4F6		MVmzJIg>		M{PQWWlv\HWldHnvckBw\iCjbIDoZUB1fWK3bHnuJIFk\XS7bHH0bY9vKHerdHigSWM2OCCxZjCwMlI2KM7:TR?=	MnnaNVkxQDR\|OUW=
HeLa	M{D6UmtqdmG\|ZTDBd5NigQ>?		M1PocFE2KG2rbh?=	M4TZd2ROW09?	MVjJcohq[mm2aX;uJI9nKEiGQVO2JIZzd21iboXjcIVieiCneITyZYN1KHerdHigTWM2OCCxZjCwMlA5PTVizszN	NFfYSmkyQTB7M{i4OC=>
HeLa	M1vkemtqdmG\|ZTDBd5NigQ>?		Mnr5NVUhdWmw	MkGzSG1UVw>?	M4fPPGlvcGmkaYTpc44hd2ZiSFTBR\|gh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFEvQDZizszN	MVuxPVA6Ozh6NB?=
NCI-H69	NV;hcGUyS3m2b4TvfIlkKEG\|c3H5		MonzO\|IhcA>?	M4CybGROW09?	MmjFTWM2OD1{LkC2JO69VQ>?	NXj4dVdVOTlyOUO4PFQ>
SKMES1	MlnwR5l1d3SxeHnjJGF{e2G7		MVS3NkBp	NGjQbpVFVVOR	NWnueGNmUUN3ME2yMlQzKM7:TR?=	MVyxPVA6Ozh6NB?=
S2	MnzPT4lv[XOnIFHzd4F6	M4LGNlAvOS1zMDFOwG0>	MlywNUBp		NEPTeXhKdmirYnn0bY9vKG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBJTEGFMTDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDBwMEW5JO69VQ>?	NIrIbXIyQTNzN{S1NC=>
SHSY5Y	NWHvOFFrU2mwYYPlJGF{e2G7	MoDUNVAh\|ryP	Ml\WOFghcA>?	M3L4UGROW09?	M1HieWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61JO69VQ>?	NI\OPVMyQTN2NEG3OS=>
SHSY5Y	MULDfZRwfG:6aXOgRZN{[Xl?	NX7iNGFkOTBizszN	NGq3epg1QCCq	NXzQPIRUTE2VTx?=	M2POUmlEPTB;MjFOwG0>	M4nOTFE6OzR2MUe1
DMS114	M1zKeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXfvUIVyPDhiaB?=		MV3HTVUxRTJwOTFOwG0>	MYKxPVQyQTJyNR?=
HBC5	NFzUVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVvWWm4yPDhiaB?=		MV\HTVUxRTF5IN88US=>	MofjNVk1OTl{MEW=
SNB78	NXmwZ\|NrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHz2[Gw1QCCq		M{frfWdKPTB;MU[g{txO	M3\jcFE6PDF7MkC1
HeLa	M13nNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVi2WYRXPzJiaB?=	M33JemROW09?	NVPMWZYyUUN3ME2wMlQ3KM7:TR?=	M{niOVE6PDRzOES2
BHK	MUPLbY5ie2ViQYPzZZk>	Ml30OUDPxE1?	MkfwNlQhcA>?	NV\DXXpbTE2VTx?=	NX;SV4hOUW6qaXLpeIlwdiCxZjDISGFEPyCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4heGyjc33hJI1mdWK{YX7lJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5?	Ml3hNVk6PjZ5OEm=
CFBE41o-	NFnDT\|hMcW6jc3WgRZN{[Xl?	NV[4Z2hOPSEQvF2=	NYPWPVh4QCCq	NXna[GVGTE2VTx?=	MXPJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcHmyZYLhZ4V1gWyjdHnvckBw\iCqaYP0c45mKEh\|	MXqxPVk3Pjd6OR?=
CFBE41o-	NWPVeYMzU2mwYYPlJGF{e2G7	M2XORlUh\|ryP	NHvnNYQ1KGh?	MnvtSG1UVw>?	M{m4OGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDteZRidnRiRnTlcJRiPTB6IFPGWHIheHKxdHXpckBt\X[nbB?=	NHjDbngyQTl4Nke4PS=>
CFBE41o-	MoX0T4lv[XOnIFHzd4F6	MW[xJO69VQ>?	NVWzRY9XOSCq	NHLDO5RFVVOR	NH64b41KdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gR2ZVWiCycn;0[YlvKGyndnXs	NXv6e5RqOTl7Nk[3PFk>
Primary bronchial epithelial cell	NHX2dWZMcW6jc3WgRZN{[Xl?	NGHFTJYyKM7:TR?=	MW[yOEBp	NULzWGczTE2VTx?=	NIq4XIJKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25?	MWCxPVk3Pjd6OR?=
CFBE41o-	MnSyT4lv[XOnIFHzd4F6	M4DzSVEh\|ryP	M{\LNlUh\GG7cx?=	NEP6NVBFVVOR	MkLlTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDzeIFjcWyrenH0bY9vKG:oIF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4>	MlTUNVk6PjZ5OEm=
CFBE41o-	NHSyUm1McW6jc3WgRZN{[Xl?	Mn[0NUDPxE1?	NYPtfY5vOjRiaB?=	MUPEUXNQ	NUfNRpJIUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBH\GWudHG1NFghS0[WUjDwdo91\WmwIITyZYZncWOtaX7n	MlPzNVk6PjZ5OEm=
CFBE41o-	MWrLbY5ie2ViQYPzZZk>	NY\mWJFkPSEQvF2=	NULZN25LOjRiaB?=	NX3CWXJsTE2VTx?=	Mm\STY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDyZZRmKG:oIH3heJVz[XSrb36gc4YhS0[WUjDwdo91\WmwIITvJIl1eyCpbInjc4Zwem1?	M3jud\|E6QTZ4N{i5
CFBE41o-	MkWzT4lv[XOnIFHzd4F6	NYLsflhYPSEQvF2=	MkCxNlQhcA>?	M3PpVWROW09?	NIXrUJhKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJN1[WKrbHn0fUBw\iCIZHXseIE2ODhiQ1\UVkBxem:2ZXnu	MUexPVk3Pjd6OR?=
CFBE41o-	M3rhZWtqdmG\|ZTDBd5NigQ>?	M3TiTFUh\|ryP	MU[yOEBp	M4jQXmROW09?	NWLoOIVCUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDjc5Jz\WO2aX;uJI9nKG23dHHueEBH\GWudHG1NFghS0[WUjD0doFn\mmla3nu[{B1dyClZXzsJJN2em[jY3WgZZMh\2y7Y3;mc5Ju	MYKxPVk3Pjd6OR?=
Primary bronchial epithelial cell	MVvLbY5ie2ViQYPzZZk>	M{KxcFUh\|ryP	MX[yOEBp	NEfuUXhFVVOR	NXzRUYdRUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25?	M1HiXFE6QTZ4N{i5
Primary bronchial epithelial cell	NXu4dYtVU2mwYYPlJGF{e2G7	NX\lXnNEOSEQvF2=	MmHuPVYhcA>?	NYfWNmJsTE2VTx?=	NVzMToc1UW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB{cG:{dDDjbZJkfWm2IHP1dpJmdnS\|	NHG2em8yQTl4Nke4PS=>
BxPC3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NY\YNZJXPzJiaB?=		MXrJR\|UxRTJwNzFOwG0>	NY\uTWVKOjBzNEO3O\|g>
CAL27	M1u4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVm3NkBp		MXPJR\|UxRTNwN{Kg{txO	NUTBXll5OjBzNEO3O\|g>
Capan1	M4HSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYK3NkBp		Mn\VTWM2OD15LkOg{txO	NIfMbJMzODF2M{e3PC=>
HCC827	M2TPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHPUT5k4OiCq		NYnldlJ3UUN3ME2xMlgh\|ryP	MkLFNlAyPDN5N{i=
LNCAP	MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkLXO\|IhcA>?		Mn;hTWM2OD1yLkW4JO69VQ>?	NUnWOpJqOjBzNEO3O\|g>
NCI-H2122	MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWf4NGptPzJiaB?=		M4j2U2lEPTB;Nz61JO69VQ>?	MYOyNFE1Ozd5OB?=
NCI-H358	M3rV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NU\KdllDPzJiaB?=		MX7JR\|UxRTJwNTFOwG0>	M4DlXVIxOTR\|N{e4
SCC15	Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3LR[lczKGh?		M1rpVmlEPTB;Mj60PUDPxE1?	MX[yNFE1Ozd5OB?=
SCC25	M3;hVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1XucVczKGh?		NF31OoFKSzVyPUGuPVMh\|ryP	MnzFNlAyPDN5N{i=
SKHEP1	M1z4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1PNSVczKGh?		MoK2TWM2OD1\|LkS2JO69VQ>?	MmrkNlAyPDN5N{i=
BJ	M3PlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;mSlExOCEQvF2=	NXOwWGhmPDhiaB?=	NYe4ZWtxTE2VTx?=	MkLGS5Jwf3SqIHnubIljcXSrb36gZZQhOC5yNTD0c{AyODBidV2=	NUjU[mY1OjBzNEO4OFA>
MUF	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF60dWoyODBizszN	NGLnfWs1QCCq	Mmj5SG1UVw>?	M1rBNGdzd3e2aDDpcohq[mm2aX;uJIF1KDBwMEWgeI8hOTByIIXN	MlL4NlAyPDN6NEC=
Caco-2	M3eyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU[xNFAh\|ryP	NGrXb401QGh?	NGfEfmJFVVOR	NX2zeIVmUUN3ME24MlEh\|ryP	M4jzWlIxOTR\|OESw
Caco-2	Mn;UT4lv[XOnIFHzd4F6	NHj1[nA2KM7:TR?=	MlS2OEBp	NX7ufY1{TE2VTx?=	NIPUNGNKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIFk\XS7bHH0bY9vKEmFNUCgc4YhOC5yM{eg{txO	NYDrdGxrOjBzNEO4OFA>
Caco-2	M1TCRWtqdmG\|ZTDBd5NigQ>?	MUKwMlMyPiCwTTD0c{A{OS54IN88US=>	MYq0JIg>	MXXEUXNQ	M{\LSGV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMTD3bZRpKEmFNUCgc4YhOC5zMUmg{txO	NGPtN4ozODF2M{i0NC=>
Caco-2	NXHvO5E1U2mwYYPlJGF{e2G7	NUW1[lFjOC5\|MU[gcm0hfG9iM{GuOkDPxE1?	MkTDOEBp	MWXEUXNQ	Ml7HSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN\|IIfpeIghUUN3MDDv[kAxNjF2NzFOwG0>	NX[2VmRkOjBzNEO4OFA>
Caco-2	M2[zOWtqdmG\|ZTDBd5NigQ>?	NFnvbYs3NjN{IH7NJJRwKDZ\|MjFOwG0>	MYi0JIg>	MYfEUXNQ	NXuydpM3TXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO1JJdqfGhiSVO1NEBw\iBzMj62JO69VQ>?	M4jsOVIxOTR\|OESw
Caco-2	MkflT4lv[XOnIFHzd4F6	NUfjXWVsPi5\|MjDuUUB1dyB4M{Kg{txO	MXm0JIg>	NWPPNol{TE2VTx?=	MU\FfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzdid3n0bEBKSzVyIH;mJFQyKM7:TR?=	M{T4V\|IxOTR\|OESw
Caco-2	Ml;aT4lv[XOnIFHzd4F6	M{fQUFAvOzF4IH7NJJRwKDNzLk[g{txO	M4XVTFQhcA>?	MYDEUXNQ	NEfmW5RGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{[=	M17FR\|IxOTR\|OESw
HepG2	NYH3T2ZPU2mwYYPlJGF{e2G7	NHP5TZY2KM7:TR?=	NGXS[Ig3cA>?	MmPUSG1UVw>?	M17OTmlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgZYNmfHmuYYTpc44>	NYW5U\|dmOjBzNEO4OFA>
HepG2	MofqT4lv[XOnIFHzd4F6	MnHzOUDPxE1?	Mk\POog>	MWPEUXNQ	MkTkTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDofZBmemGlZYT5cIF1cW:w	MWeyNFE1Ozh2MB?=
HepG2	NXHObZhYU2mwYYPlJGF{e2G7	NGPVWGo2KM7:TR?=	M3GyZVZp	M1r6R2ROW09?	NWLoU\|RXUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQh[WyyaHGteJVjfWyrbjDhZ4V1gWyjdHnvci=>	NYXLSXQ4OjBzNEO4OFA>
HepG2	NVnzdHUyU2mwYYPlJGF{e2G7	MWS1JO69VQ>?	M4fmNVZp	Mkj4SG1UVw>?	NYTlTmNJUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQhUDNxSESgbIl{fG:wZTDhZ4V1gWyjdHnvci=>	NUDKU5ROOjBzNEO4OFA>
COLO205	NGPHeItMcW6jc3WgRZN{[Xl?	NGmxUYMyOCEQvF2=	MWKyOEBp	NEnJNoNFVVOR	NEPyendKdmirYnn0bY9vKG:oIFjERWMyKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBpcXO2b37lJGg{KGGlZYT5cIF1cW:wIIfpeIghUUN3MDDv[kAzNjJizszN	M2i3S\|IxPDVzM{e4
SCC4	MXfLbY5ie2ViQYPzZZk>	NH3yWnIyKM7:TR?=	MUOyOIg>		MkTFTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIT1ZpVtcW5iYXPleJlt[XSrb36=	Mn24NlA1PTJ{MkW=
SCC4	MXXLbY5ie2ViQYPzZZk>	Mo\YNUDPxE1?	MUmyOIg>		NFO1bmtKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDhZ4V1gWyjdHnvci=>	M{XVZlIxPDV{MkK1
SCC4	M{\SW2Z2dmO2aX;uJGF{e2G7	NVnM[WM6OSEQvF2=	MUC1JI1qdg>?		M13wO2Fod26rc4SgZYN1cX[rdImgZZQhXkSUIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCFWWCyOEBo\W6nIHX4dJJme3Orb36=	MXmyNFQ2OjJ{NR?=
NB4	M2K4SmZ2dmO2aX;uJGF{e2G7	MmC0OUDPxE1?	MoW0NlQhcA>?	NYHabnhpTE2VTx?=	NEKx[ItE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4N2dXWuYYTpc44h[XRicILlMWcyKHCqYYPl	NEC3[oYzODR7MUS0NC=>
NB4	MkT3T4lv[XOnIFHzd4F6	M1n4WVUh\|ryP	MojONlQhcA>?	MX\EUXNQ	MX3Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iYXPleJlt[XSnIIT1ZpVtcW5ibHX2[Yw>	MlG2NlA1QTF2NEC=
NB4	MlvpSpVv[3Srb36gRZN{[Xl?	MUG1JO69VQ>?	NVqyc2R6OjRiaB?=	NH;lS3ZFVVOR	NG\IUpZKdmS3Y4Tpc44hd2ZicEKxW2FHOS:FSWCxJIV5eHKnc4Ppc44>	M4fzXFIxPDlzNESw
NB4	NG\XZoRMcW6jc3WgRZN{[Xl?	NE[wXlk2KM7:TR?=	NYXxWXo4OjRiaB?=	MU\EUXNQ	NX\GZmdiUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMh[WOndInsZZRqd25?	M171[VIxPDlzNESw
NUGC3	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nvS2dKPTB;Mj65OEDPxE1?	NEHwdYgzODh3MEm3NS=>
A549	MmO4SpVv[3Srb36gRZN{[Xl?	NHnTNWk2KM7:TR?=	MVqzJIg>	MWDEUXNQ	MonkTY5lfWO2aX;uJI9nKGG3dH;wbIFogSCrbjDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEyFM1nJ	MYSyNFg2PTJyOB?=
HUT78	NGTteI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUO3NkBp	M3jYb2ROW09?	NGKySppIUTVyPUCuN{DPxE1?	MVmyNFg5PDJyOB?=
U937	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUS3NkBp	MYTEUXNQ	MmjoS2k2OD1yLkO5JO69VQ>?	MV6yNFg5PDJyOB?=
A431	NF:2[2JEgXSxdH;4bYMhSXO\|YYm=		MUe3NkBp		NWHte2VlS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR\|MTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIIfpeIghUUN3MDDv[kA1NjJizszN	NHfOdHAzOTB6ME[yPS=>
A549	M2XEPWN6fG:2b4jpZ{BCe3OjeR?=		MXy3NkBp		MmTOR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISGFEKHerdHigTWM2OCCxZjCxMlgh\|ryP	NXfYWZZbOjFyOEC2Nlk>
CAL27	Mk[2R5l1d3SxeHnjJGF{e2G7		MoPPO\|IhcA>?		NUDW[nl{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0GOMkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEmFNUCgc4YhOy5{IN88US=>	M3rRUFIyODhyNkK5
HeLa	MV7DfZRwfG:6aXOgRZN{[Xl?		NV\xS5NVPzJiaB?=		NVHLe\|FLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTEGFIIfpeIghUUN3MDDv[kAyNjVizszN	MYGyNVA5ODZ{OR?=
Sf21	NUnETWRiU2mwYYPlJGF{e2G7		M{\Qd\|MhcA>?		MWrJcohq[mm2aX;uJI9nKE[uYXegeIFo\2WmIHj1cYFvKHKnY3;tZolv[W62IFjERWM5KGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU4zKM7:TR?=	M4W0NlIyODhyNkK5
SKBR3	M3;hUGN6fG:2b4jpZ{BCe3OjeR?=		MVy3NkBp		MlyyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tDWjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk43KM7:TR?=	NHTPOWwzOTB6ME[yPS=>
SKOV3	M1PPdmN6fG:2b4jpZ{BCe3OjeR?=		M17rPFczKGh?		MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCyMlIh\|ryP	MofzNlExQDB4Mkm=
COR-L23	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPnN\|cyOCEQvF2=	MlLDO\|IhcA>?	NUDoVmNFTE2VTx?=	NHnRNZhIUTVyPUGuNUDPxE1?	NUSzXmN7OjFyOEC2OFc>
DU145	MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX[xNEDPxE1?	Ml7rO\|IhcA>?	M{\rd2ROW09?	Ml74S2k2OD1zLkC1JO69VQ>?	MV6yNVA5ODZ2Nx?=
LoVo	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vpW\|ExKM7:TR?=	MVG3NkBp	NX\QeoROTE2VTx?=	NFvYPYVIUTVyPUGuO{DPxE1?	MnHCNlExQDB4NEe=
MCR5-SV2	NEf4Z2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXGxNEDPxE1?	NIfIPZY4OiCq	MUnEUXNQ	NU\yNFY6T0l3ME2yMlEh\|ryP	NFzqT3YzOTB6ME[0Oy=>
HCT116	M{fLe2tqdmG\|ZTDBd5NigQ>?	MkLRN\|Ah\|ryP	MVuzNEBp	NGjvW3ZFVVOR	MX3Jcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w	MYWyNVA5ODZ2Nx?=
HCT116	MWXLbY5ie2ViQYPzZZk>	MorNN\|Ah\|ryP	NH;E[Wc{OCCq	NV3GS4oyTE2VTx?=	MlzKTY5pcWKrdHnvckBw\iCKRFHDNUBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gbIl{fG:wZTDIN2s6KGGlZYT5cIF1cW:w	M3\MVVIyODhyNkS3
U937	M{n0d2tqdmG\|ZTDBd5NigQ>?	MWK1JO69VQ>?	Mmr5NlQhcA>?	NGLU[nJFVVOR	MYfJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SCKMzDheEBMQQ>?	MoHFNlEzQTJ2OUK=
U937	Ml\KT4lv[XOnIFHzd4F6	NXPDUFE2PSEQvF2=	NXjX[3dxOjRiaB?=	NXHTVoptTE2VTx?=	Mnu1TY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6\|ZnXyZZNmKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIH;mJIFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEOgZZQhUzF6	M4rSRlIyOjl{NEmy
U937	Ml7uT4lv[XOnIFHzd4F6	MVO1JO69VQ>?	NUDiXodNOjRiaB?=	M4jRZWROW09?	MmnITY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6\|ZnXyZZNmKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIH;mJJBidi2jY3X0fYxifGWmIHjpd5RwdmViSESgcIV3\Wx?	NInKcoszOTJ7MkS5Ni=>
U937	MXjLbY5ie2ViQYPzZZk>	MX21JO69VQ>?	NITmUZAyPSCvaX6=	MX\EUXNQ	MX;Jcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdiCuZY\lcC=>	NGq4bpozOTJ7MkS5Ni=>
A2780	MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnqwPVYhcA>?	NYfEcGF[TE2VTx?=	M2LHNmlEPTB;MT62NkDPxE1?	MX[yNVY{PDR\|MB?=
COLO205	NHjtVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1jTSFk3KGh?	MmnJSG1UVw>?	MkPxTWM2OD1{LkGyJO69VQ>?	NX\WXpVNOjF4M{S0N\|A>
Hep3B	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEnDRoQ1QCCq	NVvPcXBwTE2VTx?=	MYrHTVUxRTFwMkGg{txO	MXSyNVcyOjF2Nh?=
GM11272	M4faRmZ2dmO2aX;uJGF{e2G7	NGLsPHMyODBibl2=	M1rtdlczKGh?	MlHHSG1UVw>?	M2j1THJm[WO2aY\heIlwdiCxZjDN[WNxOiCvdYThcpQh\XiycnXzd4lwdiCjdDCxNEB1dyBzMECgcm0>	MoTQNlE5PDB5MU[=
CFBE41o	NHXo[3VMcW6jc3WgRZN{[Xl?	NEnndno2KM7:TR?=		MkTISG1UVw>?	NInzNVhFd3ewIILl[5Vt[XSrb36gc4YhUESDQ{egZZQhOC5{IITvJFUhfU1?	NVO5eWJFOjF7OES5OVg>
CFBE41o	NH;5XolHfW6ldHnvckBCe3OjeR?=	NWnNelZiOSEQvF2=	MVOyOEBp	MYDEUXNQ	M3\ESHJme3SxcnH0bY9vKG:oIFPGWHIh\GWudHHGOVA5KG23dHHueEB1emGoZnnjb4lv\yC2bzDj[YxtKHO3cn\hZ4Uh[XNiZ3z5Z49nd3Kvcx?=	Mlu0NlE6QDR7NUi=
DU145	M1jETGtqdmG\|ZTDBd5NigQ>?	M1eycFIvPSEQvF2=	MUSyOEBp	NXPWZWk1TE2VTx?=	M1jxcmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YheDJzd3HmNUBxem:2ZXnuJIV5eHKnc4Ppc44>	NGH1PJQzOjJ4MEG2Oi=>
DU145	M1:wS2tqdmG\|ZTDBd5NigQ>?	NXfVPWZ[PSEQvF2=	NEK4UngzPCCq	NWW0fnZuTE2VTx?=	NYTidFNYUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHjpd5RwdmViSESgZYNmfHmuYYTpc44>	NWLQ[lhyOjJ{NkCxOlY>
DU145	M3uwb2tqdmG\|ZTDBd5NigQ>?	Mom3OUDPxE1?	NVnNVIptOjRiaB?=	M324[WROW09?	M4j3VGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqaYP0c45mKEh\|IHj5dIVz[WOndInsZZRqd25?	M13WTlIzOjZyMU[2
786-0	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\5eGQ3NjJizszN	MoXzO\|IhcA>?	M4rqcWROW09?	NI\sdFFIUTVyPUOuNkDPxE1?	Ml3vNlI1OzV4Nkm=
A498	M4XHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXwWVBnPi5{IN88US=>	NVKxSFc2PzJiaB?=	NIPUdnNFVVOR	NIfHT3pIUTVyPUGuOkDPxE1?	MorrNlI1OzV4Nkm=
A549/ATCC	NGnWcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4H3UVYvOiEQvF2=	MYG3NkBp	Mmi4SG1UVw>?	MljNS2k2OD1zLk[g{txO	MUSyNlQ{PTZ4OR?=
ACHN	Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXP6Z\|NTPi5{IN88US=>	NWjsU2VxPzJiaB?=	MXTEUXNQ	NWjLOGxrT0l3ME2xMlMh\|ryP	M3K2WFIzPDN3Nk[5
BT549	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHMcWhOPi5{IN88US=>	NFLCTY84OiCq	NGn6cI5FVVOR	NF;6TGpIUTVyPUGuN{DPxE1?	NYXzdllCOjJ2M{W2Olk>
EKVX	NUPURpk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzW[oN4Pi5{IN88US=>	MWW3NkBp	MkH0SG1UVw>?	NXnXO4NxT0l3ME2xMlMh\|ryP	M2XnR\|IzPDN3Nk[5
HCT15	NEjx[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1O4WlYvOiEQvF2=	M1viUVczKGh?	NYXjPGF{TE2VTx?=	MX7HTVUxRTJwNTFOwG0>	MWqyNlQ{PTZ4OR?=
HOP92	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vNSlYvOiEQvF2=	NYnFenQ3PzJiaB?=	M1TvVmROW09?	NGr1fmpIUTVyPUSg{txO	NGHEXpMzOjR\|NU[2PS=>
IGROV1	NV;wdWdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPKRXJ4Pi5{IN88US=>	NY\HcVJYPzJiaB?=	NIj0SJlFVVOR	NHnENJVIUTVyPUGuN{DPxE1?	M3nxZVIzPDN3Nk[5
LOXIMVI	NEjQOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXVS5R6Pi5{IN88US=>	M2\5eVczKGh?	MnfpSG1UVw>?	NXy4RVZ1T0l3ME2xJO69VQ>?	NEi4Om0zOjR\|NU[2PS=>
M14	NGPqbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;lOk4zKM7:TR?=	MUm3NkBp	NFL6UWVFVVOR	NUC4e4pqT0l3ME2xMlMh\|ryP	NITFbYEzOjR\|NU[2PS=>
MALME-3M	NFrZcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfwV4w3NjJizszN	NXLDOoV1PzJiaB?=	NF73SnhFVVOR	MljYS2k2OD1yLkOyJO69VQ>?	NGPxblEzOjR\|NU[2PS=>
MCF10A	M1rIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HSTVYvOiEQvF2=	MVq0PEBp	MYTEUXNQ	M4OxZmdKPTB;OT62JO69VQ>?	NUD2dVZ7OjJ2M{W2Olk>
MDA-MB-435	MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzwOk4zKM7:TR?=	NEjNNoM4OiCq	MV7EUXNQ	MXHHTVUxRTBwNTFOwG0>	MmrINlI1OzV4Nkm=
MDA-MB-468	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUG2MlIh\|ryP	Ml;IO\|IhcA>?	MkK2SG1UVw>?	MmDIS2k2OD1yLk[zJO69VQ>?	NYrFO3JkOjJ2M{W2Olk>
MOLT4	NIHlTJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvkOk4zKM7:TR?=	MkixO\|IhcA>?	MWDEUXNQ	NX25bpVlT0l3ME2wMlQh\|ryP	M2DGVlIzPDN3Nk[5
NCI-ADR-RES	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIezWoo3NjJizszN	MXu3NkBp	NEnHNodFVVOR	NWXFU2tLT0l3ME2wMlE3KM7:TR?=	M{K5flIzPDN3Nk[5
NCI-H23	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mon4Ok4zKM7:TR?=	M4P4RlczKGh?	NG[xe\|dFVVOR	Ml7IS2k2OD1zIN88US=>	Mor3NlI1OzV4Nkm=
NCI-H322M	M4Oxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV[2MlIh\|ryP	MUW3NkBp	MoXySG1UVw>?	NXfqZVJWT0l3ME2wMlc6KM7:TR?=	NYf3UHA4OjJ2M{W2Olk>
NCI-H460	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jXS\|YvOiEQvF2=	Ml3xO\|IhcA>?	MXvEUXNQ	NUjqW2M6T0l3ME2wMlc6KM7:TR?=	MXSyNlQ{PTZ4OR?=
NCI-H522	NFzJTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXO2MlIh\|ryP	M3T3XVczKGh?	MVTEUXNQ	NHjJcHlIUTVyPUCuOUDPxE1?	NUPVZpAxOjJ2M{W2Olk>
OVCAR3	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:xUlYvOiEQvF2=	MkjLO\|IhcA>?	M2TNR2ROW09?	MWnHTVUxRTFwMzFOwG0>	M2frelIzPDN3Nk[5
OVCAR4	M3PwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWS2MlIh\|ryP	MXy3NkBp	NIn5NYFFVVOR	NWXicXhkT0l3ME20JO69VQ>?	NYL2OWgxOjJ2M{W2Olk>
OVCAR5	NHW0SWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M165S\|YvOiEQvF2=	MWK3NkBp	NUXiWHhqTE2VTx?=	NFLFXIFIUTVyPUCuO\|kh\|ryP	NV\pU2ljOjJ2M{W2Olk>
OVCAR8	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jFO\|YvOiEQvF2=	MX63NkBp	NH3pOWpFVVOR	MmraS2k2OD1yLkWg{txO	M{\1NFIzPDN3Nk[5
RXF393	M3fqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFizRok3NjJizszN	NF;TTJc4OiCq	NIe1VolFVVOR	Ml7oS2k2OD1zLkOg{txO	M2rU[FIzPDN3Nk[5
SF268	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\3O\|A3Pi5{IN88US=>	M2TyR\|czKGh?	NWjW[nJmTE2VTx?=	MoXxS2k2OD1zLk[g{txO	NFfo[nAzOjR\|NU[2PS=>
SF295	NYjWSppZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\PemdFPi5{IN88US=>	NHfJOXM4OiCq	MnXwSG1UVw>?	NFTnTHpIUTVyPUGuOkDPxE1?	NHv6eoUzOjR\|NU[2PS=>
SF539	M3TNTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnKeHc3NjJizszN	M3fMRVczKGh?	NGW5NHRFVVOR	NFjDVZZIUTVyPUKg{txO	MoXtNlI1OzV4Nkm=
SK-MEL-2	M3WwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HIelYvOiEQvF2=	MVi3NkBp	NHfwW5dFVVOR	Mo\NS2k2OD1zLkOg{txO	NH3td2QzOjR\|NU[2PS=>
SK-MEL-28	M1vCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWq2MlIh\|ryP	NVX4SY1FPzJiaB?=	NEHrb5RFVVOR	MY\HTVUxRTFizszN	MVuyNlQ{PTZ4OR?=
SK-MEL-5	M134fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\3[po2Pi5{IN88US=>	MXq3NkBp	NFTIe\|RFVVOR	Ml3XS2k2OD1yLk[zJO69VQ>?	M3njRlIzPDN3Nk[5
SKOV3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2[4ZlYvOiEQvF2=	NFfh[nc4OiCq	NIXBeldFVVOR	Ml3qS2k2OD1zIN88US=>	NUP0enU{OjJ2M{W2Olk>
SN12C	MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX62MlIh\|ryP	M1LWUFczKGh?	NGfKfY5FVVOR	Ml\OS2k2OD1{IN88US=>	MXuyNlQ{PTZ4OR?=
SNB19	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fYb\|YvOiEQvF2=	MUm3NkBp	MUfEUXNQ	MnHtS2k2OD1yLk[zJO69VQ>?	M1i4[lIzPDN3Nk[5
SNB75	NWjB[npQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX:2MlIh\|ryP	M2m1SlczKGh?	M37RZ2ROW09?	MkKwS2k2OD1yLke5JO69VQ>?	NWHjc\|FjOjJ2M{W2Olk>
SR	M4L0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jYRlYvOiEQvF2=	NFXiT204OiCq	NFPSRmlFVVOR	M2nSZ2dKPTB;MD60JO69VQ>?	MniwNlI1OzV4Nkm=
T47D	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLiSnFnPi5{IN88US=>	NGDsUZc4OiCq	NIfV[IlFVVOR	M{C5PWdKPTB;MD61JO69VQ>?	NFG0XYozOjR\|NU[2PS=>
TK10	NY\o[XhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX[2MlIh\|ryP	M2WyXFczKGh?	NXLISJU3TE2VTx?=	NWXMNXA6T0l3ME2wMlY{KM7:TR?=	M1npclIzPDN3Nk[5
UACC257	MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPOOm5LPi5{IN88US=>	MV[3NkBp	MWDEUXNQ	NUe2VI1rT0l3ME2wMlUh\|ryP	M13XNVIzPDN3Nk[5
UACC62	Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVG2MlIh\|ryP	NVqy[XhrPzJiaB?=	MW\EUXNQ	MUDHTVUxRTBwNDFOwG0>	M4DhN\|IzPDN3Nk[5
UO31	NGTnfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3v2VVYvOiEQvF2=	MYS3NkBp	MXTEUXNQ	MmDvS2k2OD1yLkWg{txO	Ml;1NlI1OzV4Nkm=
Hep3B	Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MonKOFghcA>?	MYTEUXNQ	NH:1[FNIUTVyPUCuOlkh\|ryP	NWqzfXRCOjJ2M{m4OlM>
BE(2)-C	NVj3e2hTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M33sZ\|czKGh?	MkX5SG1UVw>?	M3KxcGlEPzB;MjFOwG0>	MYqyNlk{OjNzNh?=
Bel7402	NIHZPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn7DO\|IhcA>?	NES1W5RFVVOR	MlzmS2k6OD1zNzFOwG0>	NIHLWVYzOzB4MUO3Oi=>
Bel7404	NYPxTHdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEn5bmM4OiCq	MnH2SG1UVw>?	M1rxcmdKQTB;MUig{txO	NFGzO3MzOzB4MUO3Oi=>
BGC823	NILpfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3:5flczKGh?	M4rXZWROW09?	M4HaVmdKQTB;Nz61JO69VQ>?	MkLRNlMxPjF\|N{[=
MGC803	M3vxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWq3[\|ZwPzJiaB?=	NXfZUm8xTE2VTx?=	NXfuUWdRT0l7ME2xNE45KM7:TR?=	NFrWNG4zOzB4MUO3Oi=>
SGC7901	MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NInwc4M4OiCq	NEXuWmdFVVOR	MYnHTVkxRTlwNDFOwG0>	NEGxSWozOzB4MUO3Oi=>
SKHEP1	NWPXZpRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1zTblczKGh?	MYrEUXNQ	M4jEOmdKQTB;MUeg{txO	Mor2NlMxPjF\|N{[=
SMMC7721	NIPDd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NY\SR3B1PzJiaB?=	M17Lb2ROW09?	M4TNVGdKQTB;MkCg{txO	Mnq1NlMxPjF\|N{[=
NUGC3	NXjxSZA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWGxNEDPxE1?			NWW1RYNOT0l;Mj65OEDPxE1?	M4jNflI{OTZ\|M{Oy
A2780 CisR	MYXLbY5ie2ViQYPzZZk>		MWmxPEBp		MoLiTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkS0JO69VQ>?	MoPtNlMzPTJ4MEO=
CAL27 sens	M3P0OWtqdmG\|ZTDBd5NigQ>?		NWfsVW17OThiaB?=		MoDnTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkO2JO69VQ>?	MUmyN\|I2OjZyMx?=
CAL27 CisR	MnToT4lv[XOnIFHzd4F6		MV[xPEBp		NEHVfYZKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOlEh\|ryP	MnzjNlMzPTJ4MEO=
KYSE-510 CisR	MoXRT4lv[XOnIFHzd4F6		MVGxPEBp		NV7qflVRUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlU6KM7:TR?=	NG\DfXUzOzJ3Mk[wNy=>
KYSE-510 sens	NIfaeXZMcW6jc3WgRZN{[Xl?		M33FV\|E5KGh?		M1rRRWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD63JO69VQ>?	MlTFNlMzPTJ4MEO=
MDA-MB-231 sens	NEnYO21McW6jc3WgRZN{[Xl?		NXjOUI9[OThiaB?=		M2HTSWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	MmjGNlMzPTJ4MEO=
MDA-MB-231 CisR	MYLLbY5ie2ViQYPzZZk>		MUGxPEBp		NH3ScYFKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOlEh\|ryP	MnzuNlMzPTJ4MEO=
ES2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVO0PEBp	NEjMUZFFVVOR	MXLJR\|UxRTF{Lkeg{txO	NG\aO4UzOzR7M{S0PS=>
MDA-MB-231	MVLLbY5ie2ViQYPzZZk>	Ml2yNVAh\|ryP	NV7Semd1OzBibXnu	MXzEUXNQ	M3rqfWlvcGmkaYTpc44hd2ZiSFTBR\|Ji	NIDFNIQzOzR7M{S0PS=>
MDA-MB-231	M3\LR2tqdmG\|ZTDBd5NigQ>?	NVTjOXhuOSEQvF2=	MoLrNlQhcA>?	MljaSG1UVw>?	M2[5cWlvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiYXPleJlt[XSrb36gcIV3\Wy\|IH;mJJR2[nWuaX6=	MUCyN\|Q6OzR2OR?=
HS68	Ml;TR5l1d3SxeHnjJGF{e2G7	Mkf0NVAh\|ryP	Ml32O\|IhcA>?	MXHEUXNQ	NYPz[HV4UUN3ME20MlYh\|ryP	NWLafFBLOjN3N{C1OFI>
MEF	MofDR5l1d3SxeHnjJGF{e2G7	M1nVO\|ExKM7:TR?=	NHjab244OiCq	M4jGW2ROW09?	M2GxVWlEPTB;ND60JO69VQ>?	MlfMNlM2PzB3NEK=
BGC823	M3nze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{X0dGROW09?	MVXHTVUxRTNwMEmg{txO	NH\4TVUzOzZyMUewOi=>
High5	MYPLbY5ie2ViQYPzZZk>		NWHBN4lrOjRiaB?=		M{L6W2lvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Yhf2m2aDDJR\|UxKG:oIECuNFkh\|ryP	NGnMUW4zOzZyMkWyNy=>
High5	NY\i[FdTU2mwYYPlJGF{e2G7		MlTUNlQhcA>?		NEiyN3RKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWMyKHerdHigTWM2OCCxZjCwMlEzKM7:TR?=	Mn;uNlM3ODJ3MkO=
High5	NHu1WY5McW6jc3WgRZN{[Xl?		M1TQd\|I1KGh?		NGi2fopKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWM{KHerdHigTWM2OCCxZjCwMlE4KM7:TR?=	MkjaNlM3ODJ3MkO=
A549	NHexcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVfrZWt6TE2VTx?=	NWTFO\|Q2UUN3ME2xMlA4QSEQvF2=	NY[4TpFCOjN4NESyNVA>
HCT116	NEDGe3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml61SG1UVw>?	M2DqOWlEPTB;MD63OVch\|ryP	M2jHT\|I{PjR2MkGw
K562	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmfhSG1UVw>?	NHO2WWRKSzVyPUCuOlQ2KM7:TR?=	NXqxOGh{OjN4NESyNVA>
GBC-SD	NUn1OId6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLrOUDPxE1?	MUe3NkBp	NXLKe2M5TE2VTx?=	M{fmNmlEPTB;MUSuPEDPxE1?	MV:yN\|cxPzJ4MB?=
HGC27	NFe5VIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWS1JO69VQ>?	NVLaNW9xPzJiaB?=	M3K3eWROW09?	NWDwU\|lVUUN3ME21MlQh\|ryP	NXHxNYt5OjN5MEeyOlA>
HL60	M1XoWGtqdmG\|ZTDBd5NigQ>?	NEj4bIk2KM7:TR?=	MlruNlQhcA>?	MlLjSG1UVw>?	MUPJcohq[mm2aX;uJI9nKEiGQVO=	NHi1VWczOzdyN{K2NC=>
Vero	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MojXO\|IhcA>?	M1nqNGROW09?	NVfUV\|VEUUN3ME2wMlkh\|ryP	NVj2cFh4OjN5OE[0OVI>
NCI60	Mn;hR5l1d3SxeHnjJGF{e2G7		MmrWOFghcA>?	M2T4RWROW09?	NHHRNotIUT1yLkWzJO69VQ>?	MX6yOFAyPTN{Nx?=
SW620	MXPDfZRwfG:6aXOgRZN{[Xl?		M3v2bFQ5KGh?	MYfEUXNQ	MkLsS2k:OC53NDFOwG0>	NEH5NJgzPDBzNUOyOy=>
U251	Mn\HR5l1d3SxeHnjJGF{e2G7		M3;tfFQ5KGh?	MkPFSG1UVw>?	NFvMRY1IUT1zLkWzJO69VQ>?	MoPWNlQxOTV\|Mke=
KM12	MUDDfZRwfG:6aXOgRZN{[Xl?		MlPQOFghcA>?	MXTEUXNQ	M{LhbWdKRTFwOEig{txO	MXyyOFAyPTN{Nx?=
Hs578T	M13UOWN6fG:2b4jpZ{BCe3OjeR?=		NVHoeoI3PDhiaB?=	M2\Dc2ROW09?	NILWV2ZIUT12LkizJO69VQ>?	MoP6NlQxOTV\|Mke=
MDA-MB-231	NYDHfZNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHvoeIU1QCCq		M4DkV2lEPTB;MD6xOkDPxE1?	MnvKNlQxQTVyMU[=
MCF7	NVvHZXJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NW[yRVNUPDhiaB?=		MXfHTV0xNjR3IN88US=>	NX;EbHo1OjRzMUm1OVU>
MDA-MB-435	M{L5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1TRbVQ5KGh?		NYHPVYZMT0l;MD64PEDPxE1?	NIroeY8zPDFzOUW1OS=>
AsPC1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7LN\|Ah\|ryP	NV\JWFVZPDhiaB?=	MoTySG1UVw>?	MmnkTWM2OD1\|Lk[2JO69VQ>?	NIe0O48zPDF6NUO3PC=>
Jurkat E6.1	M4\IcWtqdmG\|ZTDBd5NigQ>?		MkjDNkBp	M3LJOmROW09?	Mn7uTY5pcWKrdHnvckBw\iCKRFHDOEB4cXSqIFnDOVAhd2ZiMD6wOEDPxE1?	MWSyOFI3OTh4Mh?=
KG1	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4XT[\|Q5KGh?		NXG1[5dkUUN3ME2xMlE2KM7:TR?=	NUDscW8xOjR3MkWwNFM>
HEL	NFX5cFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV:0PEBp	NFHPWW5FVVOR	NGfmWXRKSzVyPUCuOFkh\|ryP	M4DWZVI1Pjl2MEW1
HSC3	M{\QbGN6fG:2b4jpZ{BCe3OjeR?=		NGnER3AyOiCq	NH;6[5RFVVOR	MWjJR\|UxRTBwN{Gg{txO	Mlr1NlQ4PjZ3NkC=
HT-29	M1rKbWN6fG:2b4jpZ{BCe3OjeR?=		MXWxNkBp	MWLEUXNQ	M3HD[2lEPTB;MD63NkDPxE1?	NGfxWHgzPDd4NkW2NC=>
KB	NWfCV2x4S3m2b4TvfIlkKEG\|c3H5		NELmdVMyOiCq	NIfuR2VFVVOR	M{\E[mlEPTB;MD63OUDPxE1?	NW\IclZWOjR5Nk[1OlA>
H460	MXPDfZRwfG:6aXOgRZN{[Xl?		MWCxNkBp	MXPEUXNQ	NHPQSYJKSzVyPUCuPFIh\|ryP	MWKyOFc3PjV4MB?=
MONE1	NHyzeodEgXSxdH;4bYMhSXO\|YYm=		MYixNkBp	NF\4enhFVVOR	MnP5TWM2OD1zLkG4JO69VQ>?	MVuyOFc3PjV4MB?=
MKN45	M1LtdmN6fG:2b4jpZ{BCe3OjeR?=		M4q4NFEzKGh?	NV;QTnhQTE2VTx?=	M{PlUGlEPTB;MT6yOUDPxE1?	NYfDcohiOjR5Nk[1OlA>
TSGH	MlTRR5l1d3SxeHnjJGF{e2G7		NGfscHMyOiCq	NYmxXGVQTE2VTx?=	MUHJR\|UxRTJwMEmg{txO	NEj0blAzPDd4NkW2NC=>
HL60	NGHmb41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{DaUFczKGh?	MVnEUXNQ	MnnVS2k2OD1yLkmzJO69VQ>?	M1vEelI1QTByNUCw
HEK293	NYqwSopYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHjlWHM4OiCq	M4ns[WROW09?	MYrHTVUxRTF\|IN88US=>	M{fnT\|I1QTByNUCw
Jurkat	MWHDfZRwfG:6aXOgRZN{[Xl?	MY[xNFAh\|ryP	M1XHZlczKGh?		MVnHTVUxRTBwOTFOwG0>	NH3pOJozPDlyMEe0Ny=>
GM15850	Mo\xT4lv[XOnIFHzd4F6	NHfjeFIzNjVizszN	M3PzT\|k3KGh?	MXfEUXNQ	MU\kc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgNVQh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NYH2TFQ1OTZ7MkGzOlc>
GM15850	NWn3V5JoU2mwYYPlJGF{e2G7	MYmyMlUh\|ryP	NHHH[oo6PiCq	M2[1cGROW09?	NXmwe4M6\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDViYXPleJlt[XSrb36gc4YhTliQIHflcoU>	NX;iR3JMOTZ7MkGzOlc>
GM15850	NFnCWGhMcW6jc3WgRZN{[Xl?	M1e2dlIvPSEQvF2=	M{jLU\|k3KGh?	MlPiSG1UVw>?	Mkfo[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFEzKGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	M1vLbVE3QTJzM{[3
GM15850	NVi0WXo3U2mwYYPlJGF{e2G7	M1THPFIvPSEQvF2=	Mn\PPVYhcA>?	MUPEUXNQ	NX33V2ho\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDNibInzbY5mKDliYXPleJlt[XSrb36gc4YhTliQIHflcoU>	NFe4dGwyPjl{MUO2Oy=>
GM15850	NFzkVlJMcW6jc3WgRZN{[Xl?	MWGyMlUh\|ryP	MUe5OkBp	NHPaOmZFVVOR	NHLSdFFld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhQCCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	MYmxOlkzOTN4Nx?=
GM15850	MUfLbY5ie2ViQYPzZZk>	NWLNTllUOi53IN88US=>	NVTK[mxKQTZiaB?=	MWHEUXNQ	NEXPbWFld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhOTZiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	MW[xOlkzOTN4Nx?=
GM15850	M1PjPGZ2dmO2aX;uJGF{e2G7	NYfQZVdQPSEQvF2=	Ml\uNVIhcA>?	NHzQ[4FFVVOR	NILNV\|Bp[XNibn:g[YZn\WO2IH;uJGZZViCvUl7BJIV5eHKnc4Ppc44>	MmLxNVY6OjF\|Nke=
U937	NHqxTXNMcW6jc3WgRZN{[Xl?	NFzUcFU2KM7:TR?=	MXGyOEBp	NXrNdm1zTE2VTx?=	M{H6O4hieyCwbzDl[oZm[3Rib36gZYxxcGFidIXieYxqdiCjY3X0fYxifGmxbh?=	MV:xO\|Q1Pzd3MB?=
U937	NX;OSmdXU2mwYYPlJGF{e2G7	NUnUT5FOOSEQvF2=	NIfFU5YzPCCq	MUnEUXNQ	MUnoZZMhdm9iZX\m[YN1KG:wIHHsdIhiKHS3YoXsbY4h[WOndInsZZRqd25?	MVSxO\|Q1Pzd3MB?=
PANC1	NEXPNVRHfW6ldHnvckBCe3OjeR?=	MVixJO69VQ>?	MnHZNlQhcA>?		NEL2ZWFld2W\|IH7veEBqdmO{ZXHz[UBqdiCyMkfrbZAyKGenbnWg[ZhxemW\|c3nvci=>	M4n0NFE4PTh6N{S0
PANC1	NHvBV5pHfW6ldHnvckBCe3OjeR?=	NYDxb2p4OSEQvF2=	M4jFSFQ5KCCq		MXjkc4V{KG6xdDDpcoNz\WG\|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?=	MnfpNVc2QDh5NES=
Caco-2	NF\zRndHfW6ldHnvckBCe3OjeR?=	NU\pS3BDPSEQvF2=	MVGyOEBp	NVr6W4xUTE2VTx?=	MU\kc4V{KG6xdDDpcoR2[2ViUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44>	NWLNXZJtOjBzNEO4OFA>
SCC4	NFWwT\|ZHfW6ldHnvckBCe3OjeR?=	M1r3clEh\|ryP	NEC0WWoyOCCvaX6=	Mm\FSG1UVw>?	NX\xWJFGcGG\|IH7vJIFod26rc4SgZYN1cX[rdImgZZQhXkSUIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCFWWCyOEBo\W6nIHX4dJJme3Orb36=	NVS2NpNyOjB2NUKyNlU>
A549	Mmf1SpVv[3Srb36gRZN{[Xl?	MVW1JO69VQ>?	Mni1N{Bp	M3Kz[2ROW09?	MoLC[I9meyCwb4SgbY5lfWOnIHH1eI9xcGGpeTDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=>	NVPXSoRkOjB6NUWyNFg>
HCT116	M2TGd2tqdmG\|ZTDBd5NigQ>?	NVrmfGtiOC5\|IN88US=>	MUizNEBp	NF;hW4tFVVOR	NXjzVHJr\G:nczDuc5QhcW6qaXLpeEBJTEGFMTDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKM1u5JIFk\XS7bHH0bY9v	MUiyNVA5ODZ2Nx?=
HepG2	NV7XPWpoTnWwY4Tpc44hSXO\|YYm=	MlTVNVAh\|ryP	MXmyOEBp	M1ixTWROW09?	MV7kc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJIh6eGW{YXPleJlt[XSrb36gc4YheDV\|	MkHFNlE2PDh3OEK=
GM11272	MWfGeY5kfGmxbjDBd5NigQ>?	M{PsXVAvOSEQvF2=	M37DUFczKGh?	MXvEUXNQ	MkLh[I9meyCwb4SgdoVi[3SrdnH0[UBO\UOyMjDteZRidnRiZYjwdoV{e2mxbh?=	M1TzfVIyQDRyN{G2
MDA-MB-231	Ml;1T4lv[XOnIFHzd4F6	NEXXd\|IyOCEQvF2=	M{PNXVUhdWmw	MUPEUXNQ	M17hNoRw\XNibn;0JIlvcGmkaYSgTGRCSzKj	MWKyN\|Q6OzR2OR?=
MDA-MB-231	M{\GUWtqdmG\|ZTDBd5NigQ>?	M2nINVEh\|ryP	NXz5ZXdROjRiaB?=	NHPP[3pFVVOR	NIL0OZNld2W\|IH7veEBqdmirYnn0JGhFSUN4IHHzd4V{e2WmIHHzJIFk\XS7bHH0bY9vKGyndnXsd{Bw\iC2dXL1cIlv	MnG5NlM1QTN2NEm=
K562	NHnJNW5McW6jc3WgRZN{[Xl?				M1H0PIRw\XNibn;0JIlvcGmkaYSgTGRCSw>?	MVuyN\|U6OTFzMR?=
Jurkat	MY\DfZRwfG:6aXOgRZN{[Xl?	NU\1bo1mOjBizszN	MWe3NkBp	Mmr4SG1UVw>?	MX3uc{BkgXSxdH;4bYNqfHliYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36=	NUD1fFVPOjR\|MESzOFg>
HCT116	NGC1N29CeG:ydH;zbZMhSXO\|YYm=	NUDsfZBUOyEQvF2=	NYjxfFZFOjRiaB?=	MonYSG1UVw>?	MXnkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKHB3MzDwdo91\WmwIHzleoVt	M3nEcFI1PzZ4NU[w
KASUMI-1	NF22eoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV70Z49rUUN3ME25PU4yPyCwTR?=	Mn\kV2FPT0WU
KARPAS-45	NViwdo1iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfiRlVFUUN3ME2xO\|MvQDlibl2=	NH;kbYNUSU6JRWK=
BHT-101	Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnncYhKSzVyPUK0OE4yQCCwTR?=	MXPTRW5ITVJ?
H9	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUi3dYliUUN3ME2yOVUvODRibl2=	NXTwT2tKW0GQR1XS
PA-1	MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XkUGlEPTB;Mki2MlI3KG6P	NH;Jb5RUSU6JRWK=
NEC8	NFnF[\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTJ6OT6zPEBvVQ>?	M1T3ZXNCVkeHUh?=
MHH-PREB-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TtN2lEPTB;Mkm0MlU{KG6P	NUK3eItSW0GQR1XS
NB7	MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTN2NT63OEBvVQ>?	MVzTRW5ITVJ?
A3-KAW	M4\QfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUC1SmgyUUN3ME20NFAvPTlibl2=	MkSwV2FPT0WU
NB69	MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3wSWl{UUN3ME20NVEvPzFibl2=	M3Hr[XNCVkeHUh?=
EoL-1-cell	NWDX[4h[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1P6OGlEPTB;NEW0NlUhdk1?	NVP0Z2F6W0GQR1XS
CHP-212	NUPZ[21yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fjUWlEPTB;NEW3MlU{KG6P	M13jNnNCVkeHUh?=
C2BBe1	NILhdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4P1TWlEPTB;NEeyMlE6KG6P	NVfpbJg6W0GQR1XS
697	NXvkRXFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jKOmlEPTB;NEezMlQyKG6P	NVX0VpV7W0GQR1XS
BCPAP	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\2TWM2OD13MEGuOFIhdk1?	NHLwZmlUSU6JRWK=
L-363	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTVyMz6xJI5O	NFm3RmZUSU6JRWK=
ES8	NVzWNZdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXyeoVjUUN3ME21NlMvPTNibl2=	MUfTRW5ITVJ?
BE-13	NFrNfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{X6NWlEPTB;NUK2Mlk3KG6P	NYO1fWxYW0GQR1XS
CTB-1	MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moj1TWM2OD13M{euPVIhdk1?	Ml7rV2FPT0WU
HD-MY-Z	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTsTW9MUUN3ME21N\|gvOTNibl2=	Mke5V2FPT0WU
NKM-1	M4C4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{H2b2lEPTB;NUS0MlI4KG6P	MXvTRW5ITVJ?
NCI-H720	M4TKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXlNGdKSzVyPUW2NE4yQCCwTR?=	NY\oT5RvW0GQR1XS
KY821	NUS4clBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnriTWM2OD13NkOuNlUhdk1?	M{LzV3NCVkeHUh?=
OVCAR-5	NFLVTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTV5Nj6xNUBvVQ>?	MkPCV2FPT0WU
CTV-1	MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4iwcWlEPTB;NUixMlU3KG6P	MWHTRW5ITVJ?
P12-ICHIKAWA	MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETaXm1KSzVyPUW5Ok42OSCwTR?=	NGjUNm9USU6JRWK=
DB	M{e0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnz3TWM2OD13OUiuOVchdk1?	MlHsV2FPT0WU
CHL-1	MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfn[JlNUUN3ME22OFIvODhibl2=	Mn7hV2FPT0WU
A4-Fuk	NYrtVVdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojQTWM2OD14NESuPVEhdk1?	MYHTRW5ITVJ?
MV-4-11	NWDhemFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmC5TWM2OD14NUmuNUBvVQ>?	M1vodHNCVkeHUh?=
RPMI-8226	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTZ5OD6xPEBvVQ>?	MlW0V2FPT0WU
NB14	NWTQVYVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrpTWM2OD14OU[uPVUhdk1?	MXrTRW5ITVJ?
DOHH-2	NHvD[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTdyNj62PEBvVQ>?	M3TCOHNCVkeHUh?=
D-423MG	M3q3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYn2S\|c6UUN3ME23NFYvQDlibl2=	M3K3UXNCVkeHUh?=
D-283MED	Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoT0TWM2OD15MUSuNVQhdk1?	NIrRT\|ZUSU6JRWK=
ES1	NHv1RZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrmOYdKSzVyPUeyOE41KG6P	M2jEPHNCVkeHUh?=
GOTO	M2[5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTd{OT6xNkBvVQ>?	NELhR\|FUSU6JRWK=
NCI-H209	NGPjfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLEcJR4UUN3ME23NlkvQSCwTR?=	MlfRV2FPT0WU
MOLT-13	M2jBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXDbGZzUUN3ME23N\|gvQThibl2=	M1XrTXNCVkeHUh?=
ATN-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHGTWM2OD15NECuNlghdk1?	MlHoV2FPT0WU
DU-4475	NYjBU2JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7qTWM2OD15NUGuPVEhdk1?	M4jQXHNCVkeHUh?=
NB10	NFK3WVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDqSZhCUUN3ME23OVEvQTJibl2=	NYP5[FhtW0GQR1XS
KG-1	NVPTRZk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrWTVJ7UUN3ME23O\|UvPDVibl2=	MWXTRW5ITVJ?
MOLT-4	NIPESnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXITWM2OD15OEeuOFYhdk1?	MorHV2FPT0WU
TE-1	NFHN[\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3aSYxKSzVyPUe5NU4yKG6P	M3;pOnNCVkeHUh?=
SBC-1	NWPNbWtyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfNeGZKSzVyPUe5N{45PCCwTR?=	MVjTRW5ITVJ?
HEL	M4W2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3wfZZ7UUN3ME24NFYvODhibl2=	M{f6Z3NCVkeHUh?=
SK-MEL-2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXIV5pKSzVyPUiwPU41PCCwTR?=	M1PYcHNCVkeHUh?=
KU812	NYf5fYdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7TWVRKSzVyPUixN{4yKG6P	NHXKbm5USU6JRWK=
RPMI-8866	M4\3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLBXYhCUUN3ME24NVMvPjdibl2=	M4jMT3NCVkeHUh?=
ALL-PO	M1OweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LodmlEPTB;OEG0MlY3KG6P	NXezXGNXW0GQR1XS
LU-139	M3XLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLiR21KSzVyPUiyNk45PiCwTR?=	M4LpXHNCVkeHUh?=
RS4-11	MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrZTVZPUUN3ME24N\|IvPDVibl2=	NXW0WZNjW0GQR1XS
EW-18	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn72TWM2OD16M{KuPVYhdk1?	M4jJcnNCVkeHUh?=
P30-OHK	NH7qZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\KfWlEPTB;OEO1Mlchdk1?	NXrFenpZW0GQR1XS
D-566MG	NXXuU4ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTh\|OD62NkBvVQ>?	MXrTRW5ITVJ?
HSC-4	M13uO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjwcXVKSzVyPUi0Ok42OSCwTR?=	Ml\3V2FPT0WU
QIMR-WIL	M1HKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TOOmlEPTB;OE[yMlA{KG6P	MVTTRW5ITVJ?
SW954	MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;OXmlEPTB;OE[zMlE3KG6P	NEHuN4tUSU6JRWK=
HGC-27	M13aVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4m3ZWlEPTB;OEeyMlM1KG6P	M3:wT3NCVkeHUh?=
HH	NWi5RY55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPX[5ZKSzVyPUi5OE4yOiCwTR?=	M{HwXHNCVkeHUh?=
KE-37	NVjLfJBlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTh7ND62NkBvVQ>?	MlHHV2FPT0WU
SK-N-DZ	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrKNlJmUUN3ME25NFAvPDNibl2=	MWLTRW5ITVJ?
J-RT3-T3-5	M13hS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XNNGlEPTB;OUGwMlQ6KG6P	M1zERXNCVkeHUh?=
A427	NF:1SGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\2XopKSzVyPUmyNE45PCCwTR?=	MoXaV2FPT0WU
ECC10	Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTl2NT64O{BvVQ>?	MX7TRW5ITVJ?
EW-1	NFjHUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELGbW5KSzVyPUm0O{4zPiCwTR?=	NH[wU\|FUSU6JRWK=
MIA-PaCa-2	M4XsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIW5OWlKSzVyPUm0PU4yOiCwTR?=	MnezV2FPT0WU
HCC2218	NWC1[Ix3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHIUm9jUUN3ME25OVgvPDhibl2=	M3HSUnNCVkeHUh?=
HAL-01	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\mVoZKSzVyPUm2PE4xPCCwTR?=	NU\TRmd6W0GQR1XS
RD	NH7SdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTl5ND60OUBvVQ>?	MUnTRW5ITVJ?
SK-N-AS	M1rrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1n0ZWlEPTB;OUi4MlEhdk1?	MX3TRW5ITVJ?
ML-2	NE\5SYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PXNmlEPTB;MT6wNFQxPyEQvF2=	NEG3PFFUSU6JRWK=
MEL-HO	NF;sZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7VTWM2OD1zLkCwOVgzKM7:TR?=	NUniclIyW0GQR1XS
MS-1	NVnWd5BZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoGyTWM2OD1zLkCwOlE4KM7:TR?=	NUHJRYpnW0GQR1XS
NCI-SNU-1	NUm2XVVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTFwMEKzN\|Eh\|ryP	M2rXe3NCVkeHUh?=
8505C	MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTFwMEKzN\|Eh\|ryP	NHLDTlJUSU6JRWK=
MN-60	M2nNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HESWlEPTB;MT6wNlY5KM7:TR?=	NFjLbXVUSU6JRWK=
SAS	NWfUNVc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnz0TWM2OD1zLkC0NFgyKM7:TR?=	M2TOcHNCVkeHUh?=
EFM-19	MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\aTWM2OD1zLkC0PFc6KM7:TR?=	M{\4S3NCVkeHUh?=
Ca9-22	NHz5XXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF:3[HlKSzVyPUGuNFUyODdizszN	NGfaSJlUSU6JRWK=
NBsusSR	NHqxb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33ifWlEPTB;MT6wOVE3PiEQvF2=	MnK1V2FPT0WU
NB13	NXWz[VM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\PVFZKSzVyPUGuNFU2ODFizszN	M2fncHNCVkeHUh?=
SF295	NUfkU3VzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HpNGlEPTB;MT6wOlYzPCEQvF2=	MlTYV2FPT0WU
U-2-OS	MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfHTWM2OD1zLkC3PVEyKM7:TR?=	M4P1cHNCVkeHUh?=
NCI-H526	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHT4TYdKSzVyPUGuNFgzQTFizszN	MUjTRW5ITVJ?
KMOE-2	NWPpcol{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTyTWM2OD1zLkC5OFIzKM7:TR?=	M4DJTnNCVkeHUh?=
RCM-1	NGezd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTFwMUKxNFIh\|ryP	NFvxN29USU6JRWK=
MC116	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIn0VGVKSzVyPUGuNVM3OjFizszN	NVjHPYFQW0GQR1XS
NCI-H1092	NHP3RnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTFwMUW0NFYh\|ryP	NX25W\|F6W0GQR1XS
EW-3	NHnMWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTFwMUeyNVIh\|ryP	M{PJOnNCVkeHUh?=
HCT-116	M336ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1K1WWlEPTB;MT6xO\|c2KM7:TR?=	MW\TRW5ITVJ?
MC-IXC	MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfRTWM2OD1zLkG3PFgyKM7:TR?=	NWL6eHU5W0GQR1XS
LB1047-RCC	MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn2yTWM2OD1zLkG4N\|EzKM7:TR?=	MYTTRW5ITVJ?
VM-CUB-1	NIDwTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7nS3VyUUN3ME2xMlE6OTB6IN88US=>	M{PK[HNCVkeHUh?=
NB5	NFSwNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLNbYZKSzVyPUGuNVk5PTZizszN	M3;IfnNCVkeHUh?=
SKG-IIIa	Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTFwMkO0OlQh\|ryP	MXvTRW5ITVJ?
HO-1-N-1	NW\GRnN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTFwMkO4N\|Uh\|ryP	NIj0VFNUSU6JRWK=
EFO-27	NEPP[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nzfmlEPTB;MT6yOVA1OyEQvF2=	NWLKdnEyW0GQR1XS
MHH-NB-11	NWjPXFBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjSfW9KSzVyPUGuNlg{OjlizszN	MXPTRW5ITVJ?
SW620	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\aV3lKSzVyPUGuNlkxOThizszN	M1HJVHNCVkeHUh?=
MOLT-16	M1zDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTadm45UUN3ME2xMlI6Pzl5IN88US=>	Mk[wV2FPT0WU
NTERA-S-cl-D1	NVG0[mVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2SxPGlEPTB;MT6zNVc3OSEQvF2=	MY\TRW5ITVJ?
VA-ES-BJ	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTFwM{K0O\|ch\|ryP	MojUV2FPT0WU
HCC1419	M1\JWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\oOIZnUUN3ME2xMlM1ODJ5IN88US=>	MY\TRW5ITVJ?
NCI-H69	NUfPfIk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTFwM{SxNVIh\|ryP	MW\TRW5ITVJ?
DEL	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTFwM{WxOlIh\|ryP	MnLQV2FPT0WU
LXF-289	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFz5doRKSzVyPUGuN\|UzPCEQvF2=	MmK5V2FPT0WU
EW-11	Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2f2fmlEPTB;MT6zOlAzPiEQvF2=	NXSxcXBvW0GQR1XS
KP-4	MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFf4SYdKSzVyPUGuN\|cxQDVizszN	M4DnNHNCVkeHUh?=
NOS-1	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFj1WZZKSzVyPUGuOFEyQTRizszN	MlzkV2FPT0WU
SK-NEP-1	M4Lybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfYTWM2OD1zLkSxOlk{KM7:TR?=	NVrVW\|R6W0GQR1XS
LAMA-84	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXxZoJKSzVyPUGuOFM6PDVizszN	MmPuV2FPT0WU
ES5	MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTFwNESzJO69VQ>?	M2TQZXNCVkeHUh?=
HuO9	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTFwNEWzOlIh\|ryP	NEnzNVZUSU6JRWK=
COLO-684	MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTFwNE[xNVgh\|ryP	MV3TRW5ITVJ?
EW-24	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDrTWM2OD1zLkS2OVMyKM7:TR?=	NUXMdpN4W0GQR1XS
BV-173	M4PlZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7Tc5hKSzVyPUGuOFczQTFizszN	NV\IWm04W0GQR1XS
NCI-H1770	NHfQ[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTFwNEi1N\|Yh\|ryP	NETpZoxUSU6JRWK=
HuP-T4	M1T6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITZcZZKSzVyPUGuOFk{KM7:TR?=	MnuxV2FPT0WU
TYK-nu	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTFwNEm4OVEh\|ryP	MljIV2FPT0WU
YH-13	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUWwWXY1UUN3ME2xMlQ6QDl2IN88US=>	NYToW2FtW0GQR1XS
H4	M4LHTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M320emlEPTB;MT61NFkyOiEQvF2=	NX\WW2l3W0GQR1XS
OVCAR-8	NVHYU45[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETHSW5KSzVyPUGuOVQ1PzdizszN	MlHiV2FPT0WU
NCI-H23	M1PJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTFwNUS2OFUh\|ryP	M2DtfXNCVkeHUh?=
ES7	M3LUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnj0TWM2OD1zLkW0O\|c{KM7:TR?=	NETYdYlUSU6JRWK=
COR-L88	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXKTWZKSzVyPUGuOVY1OjRizszN	Mn;wV2FPT0WU
TI-73	NGqzWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTFwNUmwOkDPxE1?	MWrTRW5ITVJ?
RT-112	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TQR2lEPTB;MT61PVI5PCEQvF2=	MVPTRW5ITVJ?
HuO-3N1	M{fuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIn4cnhKSzVyPUGuOVk{QDVizszN	NGWzUmhUSU6JRWK=
HC-1	MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\4Z4dKSzVyPUGuOVk5PjZizszN	NGnkfoxUSU6JRWK=
HT55	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITzWmpKSzVyPUGuOlUyOzFizszN	MY\TRW5ITVJ?
IA-LM	NEK4S45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2e3NGlEPTB;MT62PVI4QCEQvF2=	Mnz1V2FPT0WU
EM-2	M4nScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTrZmFKSzVyPUGuO\|AxOTRizszN	MVvTRW5ITVJ?
MHH-ES-1	NYHjNpVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3Ecm9nUUN3ME2xMlcxPDN3IN88US=>	NYD2emxsW0GQR1XS
CAL-27	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvKPFNvUUN3ME2xMlcxPjJzIN88US=>	NE\SenhUSU6JRWK=
COLO-800	NYnXUld2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXq1e5lwUUN3ME2xMlcyOTd7IN88US=>	M{XrUXNCVkeHUh?=
HCE-T	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTFwN{G1JO69VQ>?	MkDGV2FPT0WU
CAMA-1	NVfjSoE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\USGlEPTB;MT63NVk4OSEQvF2=	MlHLV2FPT0WU
LOXIMVI	NGDvT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGn6e3hKSzVyPUGuO\|IyOSEQvF2=	MmrMV2FPT0WU
NH-12	NVWwN4xHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTFwN{K2PVEh\|ryP	M1vab3NCVkeHUh?=
TCCSUP	NF3P[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjQbItKSzVyPUGuO\|I5OjlizszN	NHTwTHVUSU6JRWK=
MDA-MB-361	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIWxSVFKSzVyPUGuO\|MyPTdizszN	M{DLbXNCVkeHUh?=
EW-16	NYfyUVdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7sTWM2OD1zLke0NVA4KM7:TR?=	MYjTRW5ITVJ?
SNU-423	NXjxdFViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;CO2hEUUN3ME2xMlc2QDJ5IN88US=>	NIXUW3BUSU6JRWK=
Daoy	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIj3PYNKSzVyPUGuO\|Y{OTlizszN	Ml[4V2FPT0WU
ES4	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jxZmlEPTB;MT63PFc1OSEQvF2=	M4\tU3NCVkeHUh?=
PFSK-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTFwOECzO{DPxE1?	M2\pXHNCVkeHUh?=
ES3	NV60ZZptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTFwOEK2PFEh\|ryP	MnHHV2FPT0WU
ONS-76	M{e3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVy0WHhGUUN3ME2xMlgzQDl5IN88US=>	NVXBPFlYW0GQR1XS
JVM-3	M1LwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTFwOEW0OVEh\|ryP	M3;uVHNCVkeHUh?=
OS-RC-2	NIHpfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTFwOEexOVEh\|ryP	NVizdVVXW0GQR1XS
COLO-320-HSR	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvlW2NpUUN3ME2xMlg5OTl5IN88US=>	NI\2Z\|dUSU6JRWK=
HN	MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7qR3RkUUN3ME2xMlg5PzJ3IN88US=>	MXLTRW5ITVJ?
HT	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zjRWlEPTB;MT64PFk1PyEQvF2=	MY\TRW5ITVJ?
LoVo	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTFwOEm4NUDPxE1?	M2HkdXNCVkeHUh?=
CGTH-W-1	NIKzU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTwXlB7UUN3ME2xMlg6QTR4IN88US=>	NF3lSINUSU6JRWK=
NB6	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTFwOUGyPVgh\|ryP	MlTzV2FPT0WU
EW-22	NXPFVG9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vVbGlEPTB;MT65Nlg5PyEQvF2=	MoDLV2FPT0WU
ES6	NYfCO4JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTFwOUO2N\|Eh\|ryP	MUjTRW5ITVJ?
SCC-15	MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXjO\|E4UUN3ME2xMlk{QDF7IN88US=>	NH;OO3dUSU6JRWK=
HL-60	Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEW0cZNKSzVyPUGuPVM6ODJizszN	MmLkV2FPT0WU
human HOP-92	NXLYWIJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;rdGlEPTB;MT65OFA3PSEQvF2=	NUW2dFdUW0GQR1XS
SW626	NX\u[4Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTFwOUS4PVkh\|ryP	M{O1cnNCVkeHUh?=
HEC-1	M3LEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7OOG1sUUN3ME2xMlk2OzZizszN	NFTwRoZUSU6JRWK=
LB2241-RCC	Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnzOo1zUUN3ME2xMlk5OjNzIN88US=>	M4fsOXNCVkeHUh?=
Ramos-2G6-4C10	NX\Uc5hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zVNmlEPTB;MT65PVQ6OyEQvF2=	MYnTRW5ITVJ?
A101D	M{TBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGryeoJKSzVyPUKuNlA{ODNizszN	MWnTRW5ITVJ?
NCI-H446	NYjpWldET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXCcYxiUUN3ME2yMlA1PTl7IN88US=>	M4Xl[nNCVkeHUh?=
SBC-5	M4O4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTJwME[xOFch\|ryP	NULLXpZtW0GQR1XS
HOS	M1vIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\IepJKSzVyPUKuNFc3PTNizszN	MWPTRW5ITVJ?
K5	MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rUNmlEPTB;Mj6wO\|gyOSEQvF2=	MXzTRW5ITVJ?
HLE	NGjjN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG[wZYZKSzVyPUKuNFg2OjlizszN	M1\MbXNCVkeHUh?=
HSC-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonGTWM2OD1{LkGyPFk5KM7:TR?=	M{Ptd3NCVkeHUh?=
LCLC-97TM1	NXrXXo9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTJwMUS1PFMh\|ryP	NI[ydY9USU6JRWK=
DMS-273	NG\RW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TubmlEPTB;Mj6xOFg{PyEQvF2=	NWHGeGFrW0GQR1XS
TE-8	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWGyPZZFUUN3ME2yMlE2PzZ3IN88US=>	MX;TRW5ITVJ?
DSH1	MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTJwMU[zPVgh\|ryP	MVTTRW5ITVJ?
CAL-51	NY\j[HF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTJwMU[2PVkh\|ryP	NEnINpBUSU6JRWK=
IST-SL1	M3jadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LBeGlEPTB;Mj6xOlg1PCEQvF2=	MULTRW5ITVJ?
GCT	MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37U[GlEPTB;Mj6xO\|c4KM7:TR?=	NU\L[ox4W0GQR1XS
SW948	NEnuR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDFco5KSzVyPUKuNVg1PTZizszN	NH\LZWJUSU6JRWK=
NOMO-1	M4rIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXWzfHp3UUN3ME2yMlE6OzF5IN88US=>	M2jXd3NCVkeHUh?=
C8166	M{fVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;hTWM2OD1{LkKxN\|M1KM7:TR?=	NGDG[ZNUSU6JRWK=
OC-314	Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXITWM2OD1{LkKzNlU6KM7:TR?=	NXjjdlYzW0GQR1XS
CAL-39	M4i5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPrTWM2OD1{LkKzOlI3KM7:TR?=	M2O2RXNCVkeHUh?=
MDA-MB-453	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInzW2lKSzVyPUKuNlQzPzVizszN	NVLrVFJQW0GQR1XS
A673	M3vRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTJwMkW4OlIh\|ryP	M1zFfXNCVkeHUh?=
HTC-C3	Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3tTWM2OD1{LkK2PFUh\|ryP	MXfTRW5ITVJ?
NCI-H1666	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnGTWM2OD1{LkK4NVEyKM7:TR?=	M1HkRnNCVkeHUh?=
PSN1	M13Cd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTJwMki5NVMh\|ryP	M2jpNXNCVkeHUh?=
GI-1	M4DTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TxUGlEPTB;Mj6zNFU1OyEQvF2=	Mm\MV2FPT0WU
HuH-7	M4DIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTJwM{C2N\|ch\|ryP	MnT6V2FPT0WU
JAR	MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTJwM{G5PFch\|ryP	NGqxN4NUSU6JRWK=
5637	NV3JUVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXVXWtjUUN3ME2yMlMzOTJ7IN88US=>	MkXUV2FPT0WU
GB-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XVdGlEPTB;Mj6zNlM{PSEQvF2=	M4jsTXNCVkeHUh?=
KP-N-YS	Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fuPWlEPTB;Mj6zNlYyPSEQvF2=	M{myUHNCVkeHUh?=
OAW-42	M3TVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3H0UGlEPTB;Mj6zN\|QyPiEQvF2=	M2XJb3NCVkeHUh?=
8-MG-BA	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13tfmlEPTB;Mj6zN\|kxPiEQvF2=	NH3nR3NUSU6JRWK=
RH-18	NIrobWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrl[FNKSzVyPUKuN\|UxOjJizszN	NIjlS5NUSU6JRWK=
NCI-H1155	M32zSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTJwM{[3NlUh\|ryP	M2XKXnNCVkeHUh?=
NB17	M4fpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJwM{iyOFMh\|ryP	MX3TRW5ITVJ?
NCI-H1437	NXXZVWRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4mzemlEPTB;Mj60NVg4OyEQvF2=	M1n5TnNCVkeHUh?=
SN12C	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XrOGlEPTB;Mj60N\|IyPCEQvF2=	MXnTRW5ITVJ?
HSC-3	M3z0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTJwNES1NFkh\|ryP	MlzWV2FPT0WU
GAMG	Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTJwNES1OlEh\|ryP	NIHWW3ZUSU6JRWK=
HT-1080	NEfsWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTJwNES4OlQh\|ryP	M4WyXnNCVkeHUh?=
A549	Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTJwNES4PVMh\|ryP	NHqzbWRUSU6JRWK=
KNS-62	NFzTVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXJTWM2OD1{LkS1NFYyKM7:TR?=	MVvTRW5ITVJ?
YKG-1	M3\Hcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzTSI5KSzVyPUKuOFU1OzdizszN	NHLK[GhUSU6JRWK=
LU-134-A	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TFeWlEPTB;Mj60O\|AxQCEQvF2=	MVPTRW5ITVJ?
FADU	M2XBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4W2emlEPTB;Mj60O\|E3OiEQvF2=	M3flS3NCVkeHUh?=
TGBC11TKB	MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XlUGlEPTB;Mj60O\|E4PyEQvF2=	MnzEV2FPT0WU
HT-3	NEWyVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPx[lVKSzVyPUKuOFk2OzVizszN	MofpV2FPT0WU
NCI-H2170	NYjCfFM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX22bnJKUUN3ME2yMlUxPTR7IN88US=>	NUXoNXR6W0GQR1XS
Mo-T	M4DvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3OTWM2OD1{LkWwPVI4KM7:TR?=	M4jaNXNCVkeHUh?=
CCRF-CEM	MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTJwNUOwOFMh\|ryP	MYTTRW5ITVJ?
KU-19-19	MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLBUWJHUUN3ME2yMlU{PTF\|IN88US=>	MWTTRW5ITVJ?
NCI-H1048	M3PQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;sTWM2OD1{LkW1NFI2KM7:TR?=	NGXXbHBUSU6JRWK=
KOSC-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fJTWlEPTB;Mj61OlA4PiEQvF2=	MYfTRW5ITVJ?
A431	NGHOOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTJwNU[zN\|Uh\|ryP	MVHTRW5ITVJ?
COR-L23	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml6zTWM2OD1{LkW4OVY3KM7:TR?=	MlLCV2FPT0WU
MKN28	NUDnO4JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGSwfFJKSzVyPUKuOVkxOzdizszN	M3HSTnNCVkeHUh?=
22RV1	NFXSUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTJwNUmyO\|Qh\|ryP	Mmn0V2FPT0WU
ABC-1	NF7weFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2X1PGlEPTB;Mj62NFQ3KM7:TR?=	NFPwNGlUSU6JRWK=
NCI-H2126	M3\WOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\sU2lEPTB;Mj62NFk5PCEQvF2=	MVPTRW5ITVJ?
DoTc2-4510	M3XmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTJwNkKxPFUh\|ryP	MWrTRW5ITVJ?
SCC-4	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTJwNkOwNVIh\|ryP	MkXXV2FPT0WU
NCI-H661	M{TufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWCzd\|RUUUN3ME2yMlY1ODh3IN88US=>	MmHYV2FPT0WU
RPMI-2650	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTJwNkSxOFMh\|ryP	NG\mO3pUSU6JRWK=
NCI-H510A	NETaN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULoUolyUUN3ME2yMlY1PDJ4IN88US=>	Ml:0V2FPT0WU
BPH-1	M1nSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXwTWM2OD1{Lk[1PFUh\|ryP	NVHEOm9tW0GQR1XS
M14	MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTJwNk[5PVMh\|ryP	MmTwV2FPT0WU
G-402	NE[y[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnmR3lKSzVyPUKuO\|A1PTFizszN	MnjrV2FPT0WU
AsPC-1	M4fEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHJWG5KSzVyPUKuO\|EyPyEQvF2=	MX;TRW5ITVJ?
NB12	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2SzOWlEPTB;Mj63NVcyKM7:TR?=	MmLIV2FPT0WU
SK-HEP-1	MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTJwN{SzPVEh\|ryP	NXjCWnZpW0GQR1XS
U-266	M4[xVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGD5[YFKSzVyPUKuO\|cyOjFizszN	MYfTRW5ITVJ?
AM-38	NFTmdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnkbW82UUN3ME2yMlc4OzV3IN88US=>	MYLTRW5ITVJ?
PC-14	Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LQSmlEPTB;Mj64NFUyKM7:TR?=	MWfTRW5ITVJ?
EGI-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjJUZhoUUN3ME2yMlgyPzR\|IN88US=>	NF\aUnRUSU6JRWK=
LS-411N	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHmUo1KSzVyPUKuPFI{OyEQvF2=	M{HXPHNCVkeHUh?=
BFTC-905	NGjGVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHjdmNKSzVyPUKuPFU2OjNizszN	NI[1TohUSU6JRWK=
CaR-1	M3O3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLaWlhKSzVyPUKuPFYh\|ryP	NEToRmxUSU6JRWK=
NCI-H292	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrnTWM2OD1{Lki2OVk3KM7:TR?=	Ml7lV2FPT0WU
8305C	Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnwVo5KSzVyPUKuPFY3PDVizszN	MVXTRW5ITVJ?
SNU-449	NVzZR4h{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfYWGZKSzVyPUKuPFkyQDJizszN	NVLDdmN3W0GQR1XS
LCLC-103H	NXXVUpJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHyweYxKSzVyPUKuPVA1OzhizszN	M4n0TnNCVkeHUh?=
SW1573	MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULQNZJEUUN3ME2yMlk3ODh{IN88US=>	NGDjSGdUSU6JRWK=
MLMA	MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3y5UGlEPTB;Mj65OlcyPyEQvF2=	Mme0V2FPT0WU
NCI-H1355	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFmxbW9KSzVyPUOuNFA4QTZizszN	M{DC[nNCVkeHUh?=
RMG-I	NVvZcpZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\PUWlEPTB;Mz6wNlU6OiEQvF2=	MVjTRW5ITVJ?
BB65-RCC	NH30WJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTNwMEOzNVQh\|ryP	M{f4cHNCVkeHUh?=
PC-3	NFG1VHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXNVXVUUUN3ME2zMlA{QDd2IN88US=>	MmnVV2FPT0WU
SF268	M1\ibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vLXWlEPTB;Mz6wOFUzOyEQvF2=	MknvV2FPT0WU
NCI-H810	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HM[GlEPTB;Mz6wOFgzOyEQvF2=	NULROIh3W0GQR1XS
MEG-01	MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrodWxKSzVyPUOuNFYyPjRizszN	NWrxS4ZsW0GQR1XS
SW13	NVGxcFZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHWTWM2OD1\|LkC3PFQ4KM7:TR?=	MVPTRW5ITVJ?
RH-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVv0PFNDUUN3ME2zMlExOjd6IN88US=>	MUjTRW5ITVJ?
GT3TKB	MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULSdFZJUUN3ME2zMlEyOjh\|IN88US=>	NVvmTIY2W0GQR1XS
TK10	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{Kzc2lEPTB;Mz6xN\|czPCEQvF2=	MkjJV2FPT0WU
T-24	NYnmTINST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTaSlBSUUN3ME2zMlE2ODdizszN	NEjiflBUSU6JRWK=
A498	M3PlZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTsVFJrUUN3ME2zMlIxQDdzIN88US=>	M3e4NHNCVkeHUh?=
GR-ST	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTNwMkKxN\|kh\|ryP	NUHGNJNOW0GQR1XS
LB2518-MEL	NVK2RoNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XQc2lEPTB;Mz6yNlM6QCEQvF2=	MmH0V2FPT0WU
T47D	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rsVmlEPTB;Mz6yN\|YzPyEQvF2=	NVfnO5Q6W0GQR1XS
NCI-H1651	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLpZZpzUUN3ME2zMlI1PjR2IN88US=>	MX\TRW5ITVJ?
EC-GI-10	NGnw[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mme4TWM2OD1\|LkK2NVU{KM7:TR?=	NFPreGpUSU6JRWK=
HT-29	M4LXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHG2PIlKSzVyPUOuNlY3OTRizszN	MV7TRW5ITVJ?
GI-ME-N	Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTNwMkm1NVEh\|ryP	NGnpe4NUSU6JRWK=
SW756	MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTNwMkm2Nlkh\|ryP	NEP1cFhUSU6JRWK=
RKO	M{nwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PCWWlEPTB;Mz6zNFc2PyEQvF2=	NVfWV5c3W0GQR1XS
NCI-H1563	M3HFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4Hhc2lEPTB;Mz6zN\|AyQCEQvF2=	MlH4V2FPT0WU
DJM-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fjNWlEPTB;Mz6zO\|Y4PCEQvF2=	NELjO5pUSU6JRWK=
L-428	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTNwNECwOFUh\|ryP	NWrsOIs2W0GQR1XS
NCI-H2122	NYG1RYN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPuW4tKSzVyPUOuOFE{OTJizszN	MnXKV2FPT0WU
Ca-Ski	MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;rTWM2OD1\|LkS1OFMh\|ryP	NW\pRlJYW0GQR1XS
639-V	MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfTTWM2OD1\|LkS2NFU4KM7:TR?=	MoPJV2FPT0WU
SW1116	NEXmb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjuZ3ZiUUN3ME2zMlQ3OjZ7IN88US=>	NGW5enpUSU6JRWK=
DMS-114	M2HNVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;pcYpKSzVyPUOuOFcxPjZizszN	NEnT[XNUSU6JRWK=
MZ2-MEL	MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXxZ4tKUUN3ME2zMlQ4PjhzIN88US=>	MVjTRW5ITVJ?
COLO-829	NVPUcGpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTNTWM2OD1\|LkWwNFc{KM7:TR?=	M3\kbHNCVkeHUh?=
J82	NGi2clVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXzXXU5UUN3ME2zMlUxPTdizszN	MmPuV2FPT0WU
EW-13	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7mOnplUUN3ME2zMlUzPTFizszN	MoD5V2FPT0WU
RXF393	Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTNwNUOyPVQh\|ryP	NUPndpg5W0GQR1XS
CAL-62	NHPZb\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrFTWM2OD1\|LkW0OVE1KM7:TR?=	NUfkUIFnW0GQR1XS
OCUB-M	NV\qSHBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXWbJJUUUN3ME2zMlU1PjZ3IN88US=>	MVvTRW5ITVJ?
BT-474	M1\4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF2wdGdKSzVyPUOuOlM{OSEQvF2=	MUPTRW5ITVJ?
KYSE-180	NV3me41pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXSwN2RWUUN3ME2zMlY{Ozd{IN88US=>	M2nCNHNCVkeHUh?=
NCI-H650	NWXkVZZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDNTWM2OD1\|Lk[0Nlg4KM7:TR?=	M1L5XXNCVkeHUh?=
Detroit562	MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTieVIzUUN3ME2zMlY2ODJ{IN88US=>	NGXI[pBUSU6JRWK=
SW48	Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DUeGlEPTB;Mz62OVY2PyEQvF2=	NWrhU3hJW0GQR1XS
KYSE-450	NHX3e3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTNwNki1PFIh\|ryP	M4nac3NCVkeHUh?=
KYSE-510	NVfrXmozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTNwN{KxPFEh\|ryP	M13lWXNCVkeHUh?=
GP5d	NFjOPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTNwN{K5OUDPxE1?	M1PZVHNCVkeHUh?=
RPMI-7951	MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPiXVNOUUN3ME2zMlc1PzJ\|IN88US=>	NHT3dJRUSU6JRWK=
Becker	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzvTWM2OD1\|Lke1NFEzKM7:TR?=	M1W3W3NCVkeHUh?=
WM-115	NX\rOW5LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3H0TmlEPTB;Mz63PFE6PSEQvF2=	MU\TRW5ITVJ?
G-401	NFnLe4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXvUJNEUUN3ME2zMlc6ODh3IN88US=>	NVvT[ZFRW0GQR1XS
PANC-08-13	NYG5dFZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITmW2lKSzVyPUOuO\|k3ODJizszN	NWjTdXQ3W0GQR1XS
SW982	M4W1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvQWGpDUUN3ME2zMlgxPTVzIN88US=>	NGnQflhUSU6JRWK=
D-263MG	MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnqT2JnUUN3ME2zMlgzODVzIN88US=>	M3HHcHNCVkeHUh?=
KM-H2	NES2TohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWe1cJBIUUN3ME2zMlgzPjJ2IN88US=>	M2i0OXNCVkeHUh?=
SK-MEL-3	M2HMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVr1NWJUUUN3ME2zMlgzQDRzIN88US=>	M1PTNHNCVkeHUh?=
NCI-H1581	NInMUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTNwOES0PFgh\|ryP	Mn33V2FPT0WU
LS-123	NFrX[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnG2TWM2OD1\|Lki3PVA6KM7:TR?=	M{WxUHNCVkeHUh?=
CAKI-1	NVfFbldCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fvOmlEPTB;Mz64PVA2OiEQvF2=	NVW4RohQW0GQR1XS
MEL-JUSO	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmW5TWM2OD1\|Lki5NVU{KM7:TR?=	M3LxfXNCVkeHUh?=
HCE-4	M4Dyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDz[HlQUUN3ME2zMlkyPjZ\|IN88US=>	M4jqNXNCVkeHUh?=
TE-10	M2rTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXmN\|FKSzVyPUOuPVIxOSEQvF2=	NWDPSGFKW0GQR1XS
OVCAR-4	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDCZplKSzVyPUOuPVI5QDlizszN	Ml\JV2FPT0WU
ETK-1	M2DERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTNwOUS2N\|Uh\|ryP	NWLVRXJYW0GQR1XS
A2780	NFzkS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{T0ZWlEPTB;ND6wOVk3PiEQvF2=	MXLTRW5ITVJ?
LU-65	NELrfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULlR494UUN3ME20MlA4PjN\|IN88US=>	NXvqUpdvW0GQR1XS
BHY	NVvNXGVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzabmhKSzVyPUSuNVI1QTVizszN	NUOyb3ZyW0GQR1XS
COR-L105	NYfCO5ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTRwMUOwOVEh\|ryP	NXzKeIl1W0GQR1XS
CAL-12T	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1Hr[WlEPTB;ND6xN\|ExOyEQvF2=	MU\TRW5ITVJ?
SCH	NH;NTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXeyc4dRUUN3ME20MlE2PzR\|IN88US=>	M3PFV3NCVkeHUh?=
CW-2	NXO4TIlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTRwMUmwNFEh\|ryP	MXXTRW5ITVJ?
HCC1806	MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M124dWlEPTB;ND6yNFMyOiEQvF2=	NULQc4lOW0GQR1XS
KP-N-YN	NXjRcnN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTRwMkC5Nlch\|ryP	NGjY[o5USU6JRWK=
T98G	MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPYTWM2OD12LkKyNVU4KM7:TR?=	MoDlV2FPT0WU
CAL-54	NFHIN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGX1VY1KSzVyPUSuNlI{QDFizszN	M3rYWnNCVkeHUh?=
CAL-33	MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUGyVZFiUUN3ME20MlI{ODZ2IN88US=>	MonuV2FPT0WU
SNU-C2B	NWXYNoFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTRwMkS3Olkh\|ryP	NFnIS4FUSU6JRWK=
NUGC-3	MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTRwMkW1NFUh\|ryP	NYPvSZB6W0GQR1XS
DOK	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTRwMk[1PVMh\|ryP	M4S5eXNCVkeHUh?=
MMAC-SF	MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTRwMk[4OVkh\|ryP	M33obXNCVkeHUh?=
KYSE-70	Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTRwMkmzOEDPxE1?	MWXTRW5ITVJ?
A204	MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;Fe5BQUUN3ME20MlM2QDB\|IN88US=>	MkfpV2FPT0WU
SCC-25	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\scWlEPTB;ND6zOVgyQSEQvF2=	NXPRNpNpW0GQR1XS
EPLC-272H	NFvKSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTRwM{i5OUDPxE1?	Mn;TV2FPT0WU
CAL-120	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTRwM{i5PVIh\|ryP	NFHO[JRUSU6JRWK=
LS-513	MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHOOFhTUUN3ME20MlQzOTl6IN88US=>	NVG0d4lvW0GQR1XS
CAPAN-1	M3u3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmT3TWM2OD12LkSyN\|gzKM7:TR?=	M{DyZ3NCVkeHUh?=
ESS-1	M4DhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfFPVNRUUN3ME20MlQzPzJ2IN88US=>	MWnTRW5ITVJ?
GMS-10	MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTRwNEK4NVkh\|ryP	MV3TRW5ITVJ?
NCI-N87	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{iye2lEPTB;ND61NFg3QCEQvF2=	MVHTRW5ITVJ?
HMV-II	NXf2dm16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrmRZVbUUN3ME20MlUyPzNizszN	MWfTRW5ITVJ?
COLO-741	M1naXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXkNodKSzVyPUSuOVU6QTRizszN	MXfTRW5ITVJ?
MKN45	NFyyXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\2RlBKSzVyPUSuOVc4OzJizszN	MV;TRW5ITVJ?
OAW-28	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3NVZdKSzVyPUSuOVg{QThizszN	NGGz[GtUSU6JRWK=
OCI-AML2	NIDkcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTRwNkWyN\|gh\|ryP	NHfLPYZUSU6JRWK=
MDA-MB-231	NIK1PZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTRwN{CyOFMh\|ryP	M2D4R3NCVkeHUh?=
NCI-H1648	Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPQUI5KSzVyPUSuO\|IzPzNizszN	MnGyV2FPT0WU
NCI-H1792	NUO5PGlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXMTWM2OD12Lke2NVA4KM7:TR?=	MoDvV2FPT0WU
GCIY	NGfTc\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTRwN{e0NlQh\|ryP	M4HTeXNCVkeHUh?=
Hs-578-T	MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDLTWM2OD12Lke3OlU2KM7:TR?=	MnXVV2FPT0WU
SW962	NXzzZ5JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHL3RpNKSzVyPUSuO\|gxOTFizszN	NHLT[Y9USU6JRWK=
NCI-H630	NITnUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\ZSo9qUUN3ME20Mlc5ODhzIN88US=>	MVrTRW5ITVJ?
786-0	M4X3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvOTWM2OD12Lke4O\|c{KM7:TR?=	NEjmNYtUSU6JRWK=
FTC-133	M1fw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEi5cIVKSzVyPUSuO\|kzPjNizszN	NWixNIJFW0GQR1XS
BT-20	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4W1ZmlEPTB;ND63PVQzQSEQvF2=	M2P2OXNCVkeHUh?=
Mewo	M4PWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTRwOEG3OFch\|ryP	M{joXHNCVkeHUh?=
SW780	MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3izeGlEPTB;ND64OVc3PiEQvF2=	M3jaR3NCVkeHUh?=
OE33	NHnLdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\MOI1KSzVyPUSuPFc4OTNizszN	MojtV2FPT0WU
HCC1569	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHr5cppKSzVyPUSuPFg1PThizszN	NGHjO21USU6JRWK=
TE-6	M3zIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\ETWM2OD12LkmzPVc4KM7:TR?=	MULTRW5ITVJ?
SK-N-FI	M3rRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTRwOUS0NlEh\|ryP	MVLTRW5ITVJ?
PANC-03-27	M1PsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HWSmlEPTB;ND65PVk3OiEQvF2=	M1\LU3NCVkeHUh?=
MCF7	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTVwMEC3N\|gh\|ryP	NUnBNFNVW0GQR1XS
UACC-257	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoGwTWM2OD13LkCyPFQ2KM7:TR?=	Mn3mV2FPT0WU
SW1088	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTVwMEK5OFQh\|ryP	M3zvWXNCVkeHUh?=
A704	M{j2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTVwMEOwOkDPxE1?	MXrTRW5ITVJ?
A2058	M3\kTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvJNnk5UUN3ME21MlA2QTB6IN88US=>	NF3uO2FUSU6JRWK=
Calu-3	M1i3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjFTWM2OD13LkC2OFUzKM7:TR?=	MVLTRW5ITVJ?
RERF-LC-MS	MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvtPWVKSzVyPUWuNFY6ODNizszN	MkTvV2FPT0WU
AU565	NUDvSnl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LWeWlEPTB;NT6wPVcxOiEQvF2=	NFTGZmVUSU6JRWK=
DMS-79	NXzJfIdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUK4WFd1UUN3ME21MlE{QDh\|IN88US=>	Mmq5V2FPT0WU
DK-MG	M175XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnS5TWM2OD13LkG4OFM5KM7:TR?=	NE\YPVRUSU6JRWK=
HuCCT1	NWHRTJJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fXdWlEPTB;NT6yN\|g2PiEQvF2=	M1TKOnNCVkeHUh?=
HT-144	M13Pfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\jUZVKSzVyPUWuNlQ6QDdizszN	NVvnUYl4W0GQR1XS
M059J	M2XwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPhTWM2OD13LkK1O\|Yh\|ryP	MmrmV2FPT0WU
COLO-792	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHS4blZKSzVyPUWuNlY{PTZizszN	NYDtVHNTW0GQR1XS
SF539	NIHsdnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrQV\|ZyUUN3ME21MlI3PjN{IN88US=>	Mnq3V2FPT0WU
SK-UT-1	M2XTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HRbmlEPTB;NT6yO\|c2OSEQvF2=	MkLpV2FPT0WU
NCI-H1703	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPCeIxKSzVyPUWuN\|U5OjZizszN	MmXFV2FPT0WU
SW837	NGXsPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTVwM{e4O\|gh\|ryP	NX\yd2FqW0GQR1XS
U251	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3oeY5KSzVyPUWuN\|kxQTZizszN	MXTTRW5ITVJ?
SW1710	M4fvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XxVWlEPTB;NT60NVU2PCEQvF2=	M2PZT3NCVkeHUh?=
NCI-H1299	M3;yW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfLXYY5UUN3ME21MlQ3OzN3IN88US=>	MkTPV2FPT0WU
RVH-421	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTVwNEm5NFgh\|ryP	M37oZnNCVkeHUh?=
UM-UC-3	NWrj[GJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTVwNkK2OVEh\|ryP	MlXJV2FPT0WU
MDA-MB-175-VII	NHTmbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PxOmlEPTB;NT62OFA1OSEQvF2=	MnLGV2FPT0WU
KYSE-270	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPwTWM2OD13Lk[2NFMyKM7:TR?=	NUPje2o6W0GQR1XS
COLO-668	NEHRTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnsTlBKSzVyPUWuO\|E{OiEQvF2=	M2DuN3NCVkeHUh?=
LN-405	M{ewbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml71TWM2OD13LkezNFg2KM7:TR?=	MUXTRW5ITVJ?
HT-1376	M3jSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrnXlJKSzVyPUWuO\|gxPTJizszN	M37lTXNCVkeHUh?=
769-P	M1rmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XnW2lEPTB;NT64OlcyQCEQvF2=	M1n0Z3NCVkeHUh?=
HuP-T3	M3HVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rSU2lEPTB;NT64PFY4PyEQvF2=	Mn;pV2FPT0WU
MDA-MB-415	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnyZlJKSzVyPUWuPVIyOzlizszN	NGTyW\|FUSU6JRWK=
MKN7	MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTVwOUi4JO69VQ>?	M1i3UnNCVkeHUh?=
KS-1	MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TPPGlEPTB;NT65PFg{PiEQvF2=	M{\mVHNCVkeHUh?=
647-V	M1r4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTVwOUmxOFgh\|ryP	NGDsRYpUSU6JRWK=
COLO-679	MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnr5TWM2OD14LkCwNlU2KM7:TR?=	M4\w[nNCVkeHUh?=
AN3-CA	NHztSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTZwMEO0OFEh\|ryP	MVrTRW5ITVJ?
C32	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\SOGlEPTB;Nj6xN\|A{PCEQvF2=	NIfmNYZUSU6JRWK=
KM12	NYHqOG9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjRTWM2OD14LkK0NFk6KM7:TR?=	MojjV2FPT0WU
KINGS-1	NHHpemVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrsTWM2OD14LkK2NVUzKM7:TR?=	NXHHVlZZW0GQR1XS
KYSE-410	NGHG[\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rtVmlEPTB;Nj6zNFY1PSEQvF2=	M4WwZnNCVkeHUh?=
HPAF-II	M1LRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13tVWlEPTB;Nj6zOVQ5KM7:TR?=	MUnTRW5ITVJ?
LAN-6	NH3YOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTZwNEm2N\|Eh\|ryP	NIO1dmtUSU6JRWK=
LU-99A	NFnoZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTZwNUW5PFkh\|ryP	MWrTRW5ITVJ?
SJSA-1	MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEL3fJpKSzVyPU[uOVY{PDdizszN	NETUdoFUSU6JRWK=
MSTO-211H	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzpUJRKSzVyPU[uO\|IzOzNizszN	MXjTRW5ITVJ?
SW900	NVe1R441T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTsTWM2OD14Lke2NlIyKM7:TR?=	NFTYbJhUSU6JRWK=
LNCaP-Clone-FGC	MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTZwOEC0NFMh\|ryP	NFryeFhUSU6JRWK=
OMC-1	M{Ts[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvxTWM2OD14Lki1OFAzKM7:TR?=	MV;TRW5ITVJ?
IST-MEL1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTZwOEm2Olkh\|ryP	MXXTRW5ITVJ?
TE-9	NHG1Tm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfHVXFRUUN3ME22Mlg6QDR5IN88US=>	M4\qcXNCVkeHUh?=
NCI-H2030	NVzU[pFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;LTWM2OD14LkmxNlI3KM7:TR?=	MnPpV2FPT0WU
BFTC-909	NVPhRVU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTdwMEC2OFEh\|ryP	NGrXUmZUSU6JRWK=
NCI-SNU-5	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTdwMEKxOVkh\|ryP	MljVV2FPT0WU
TE-5	NHPvfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLu[phtUUN3ME23MlAzQDhzIN88US=>	NUDSUWx7W0GQR1XS
SK-MES-1	NI\1ZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTdwMEW0Nlch\|ryP	MnG4V2FPT0WU
SHP-77	M{XoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnQTWZKSzVyPUeuNVM6PTJizszN	NXLwe5dDW0GQR1XS
NCI-H1623	M4XYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoriTWM2OD15LkG0NFczKM7:TR?=	M17wcnNCVkeHUh?=
TE-11	MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;IVmlEPTB;Nz6xOVE5PCEQvF2=	M{\QfXNCVkeHUh?=
EKVX	NHfDXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXpTWM2OD15LkG5NlY4KM7:TR?=	MYnTRW5ITVJ?
OVCAR-3	NWrLXWhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\NOGlEPTB;Nz6yNVE{OyEQvF2=	NWCxS49bW0GQR1XS
C3A	NUDJTG9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PIVmlEPTB;Nz6zOFUzKM7:TR?=	M1XFUHNCVkeHUh?=
CFPAC-1	NH60O4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXyze\|BDUUN3ME23MlM3OjJ{IN88US=>	M{\QVnNCVkeHUh?=
MG-63	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLnTWM2OD15LkSxPFQ6KM7:TR?=	NUi4e\|dMW0GQR1XS
KYSE-140	NYq3dJBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTdwNESwOlEh\|ryP	NVrZfFhCW0GQR1XS
MPP-89	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPWfoFwUUN3ME23MlU6PzJ7IN88US=>	M3fNbHNCVkeHUh?=
COLO-824	MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzjSG5KSzVyPUeuO\|I5PjNizszN	NEf6dpRUSU6JRWK=
SiHa	Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWL0fWt4UUN3ME23Mlg{PzB5IN88US=>	Mm\3V2FPT0WU
SNU-387	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fXTWlEPTB;Nz64OVM1PyEQvF2=	MlTlV2FPT0WU
A172	MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEixNHRKSzVyPUeuPFYyPzJizszN	NYPn[\|dtW0GQR1XS
COLO-680N	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXn0b2pUUUN3ME23MlkyPzNizszN	MoToV2FPT0WU
HCC1395	M3jYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHrTWM2OD16LkC1OFUzKM7:TR?=	MXHTRW5ITVJ?
NCI-H28	NHzOUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRThwMEW5OlMh\|ryP	MUTTRW5ITVJ?
LC-2-ad	M1;pcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkSwTWM2OD16LkKxPVM4KM7:TR?=	M{P0e3NCVkeHUh?=
S-117	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\HTXJKSzVyPUiuNlU{PTNizszN	MmTJV2FPT0WU
NCI-H1838	NHnZT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRThwMkW3PFEh\|ryP	NIPGeY5USU6JRWK=
PANC-10-05	M2TJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRThwM{ewOFch\|ryP	Mlq1V2FPT0WU
KALS-1	M4LnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1:w[2lEPTB;OD61NFkzQCEQvF2=	NX3ONXl1W0GQR1XS
LS-1034	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInOZYdKSzVyPUiuOVc1OzdizszN	MUDTRW5ITVJ?
TGBC1TKB	NHyzcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGC2WoVKSzVyPUiuO\|M2OzVizszN	NYKyPJRxW0GQR1XS
OE19	NH2wWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfCTIVKSzVyPUiuO\|YzPjJizszN	NU[yO3dyW0GQR1XS
D-502MG	M4DNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDSTWM2OD16Lke2PVk1KM7:TR?=	NULkTHpWW0GQR1XS
JEG-3	M1LuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRThwN{i2NVgh\|ryP	M{j2NnNCVkeHUh?=
DBTRG-05MG	NGHQW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjHTWM2OD16Lki3OVY2KM7:TR?=	NV36fWFVW0GQR1XS
ME-180	NYC3ZXp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvGVJRKSzVyPUmuNFY4OjVizszN	NIXtT4RUSU6JRWK=
NCI-H1573	M3fXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYf5UFRIUUN3ME25MlExPTN{IN88US=>	M1XxfnNCVkeHUh?=
HCC2998	MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTlwMUO2PFEh\|ryP	NYn5c5ZoW0GQR1XS
ACHN	NELYTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTlwMkS5O\|Uh\|ryP	NELPdGVUSU6JRWK=
D-392MG	NEXpfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTlwMkW3NVUh\|ryP	M1\mfXNCVkeHUh?=
no-11	NE\meGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTlwMk[wNlgh\|ryP	NIDnSHJUSU6JRWK=
KLE	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrBfFQxUUN3ME25MlMzOjN{IN88US=>	MV\TRW5ITVJ?
Calu-6	NGjFc\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmD2TWM2OD17LkO3OVI5KM7:TR?=	MnfSV2FPT0WU
LB831-BLC	NGLGenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzCTWM2OD17LkS1NVcyKM7:TR?=	MX;TRW5ITVJ?
SW684	NFm2fFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTlwNE[xNVYh\|ryP	NUPlWYg3W0GQR1XS
SH-4	MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTlwNEmzOlQh\|ryP	M{C3W3NCVkeHUh?=
IST-MES1	MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvETWM2OD17LkWxOlQ1KM7:TR?=	M4WwdHNCVkeHUh?=
Saos-2	Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTlwNUKxPVUh\|ryP	M4T1SXNCVkeHUh?=
NCI-H2087	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPOTWM2OD17Lk[3N\|UzKM7:TR?=	NUHxVHl[W0GQR1XS
SCC-9	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHntb29KSzVyPUmuO\|E5OTZizszN	NEXQTpRUSU6JRWK=
MFE-280	MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTlwN{K3PFUh\|ryP	Mly3V2FPT0WU
BEN	NFHRWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfTTWM2OD17LkiyNVU6KM7:TR?=	M3HMPHNCVkeHUh?=
CP50-MEL-B	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTlwOUK0N\|Ih\|ryP	MkXWV2FPT0WU
SK-MEL-28	MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPKR2pKSzVyPUGwMlAyQTNizszN	NWHpNoZ{W0GQR1XS
NCI-H2452	MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTFyLkG2JO69VQ>?	NEXvVFZUSU6JRWK=
NCI-H1395	MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIOxUJZKSzVyPUGwMlE4QCEQvF2=	MXjTRW5ITVJ?
NCI-H2052	MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFr4WIdKSzVyPUGwMlE5QDJizszN	MmnjV2FPT0WU
A375	MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXqwT4xjUUN3ME2xNE4zPDV{IN88US=>	NIqwempUSU6JRWK=
HCC38	NYfi[odPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHH5VnRKSzVyPUGwMlMzOiEQvF2=	MUPTRW5ITVJ?
LK-2	NYHKWJpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDVTWM2OD1zMD60NlA5KM7:TR?=	M4Hy[nNCVkeHUh?=
SF126	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rGbmlEPTB;MUCuOFczPyEQvF2=	NInv[I5USU6JRWK=
SK-MEL-1	M1OwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkC1TWM2OD1zMD63PFM5KM7:TR?=	MWHTRW5ITVJ?
ACN	M4r1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTFyLki2O\|kh\|ryP	M{jEe3NCVkeHUh?=
BB30-HNC	M{LJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;2e\|M2UUN3ME2xNE45PzFzIN88US=>	Ml;FV2FPT0WU
NCI-H747	M1jvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TES2lEPTB;MUCuPFc1PiEQvF2=	NX;JeG42W0GQR1XS
KYSE-150	NIjKNWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHH5TFJKSzVyPUGxMlA{QDdizszN	NGHKN29USU6JRWK=
D-247MG	NUDOWlg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{H6[GlEPTB;MUGuNVAxQSEQvF2=	MWnTRW5ITVJ?
BxPC-3	MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHDTWM2OD1zMT6zO\|Q4KM7:TR?=	NUT5dIhDW0GQR1XS
SK-MEL-30	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnoTWM2OD1zMT60NFc6KM7:TR?=	NGLNZ5NUSU6JRWK=
CAS-1	NGDOdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzUZWVtUUN3ME2xNU41OTB7IN88US=>	NXnQd3U1W0GQR1XS
no-10	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnj4TWM2OD1zMj6xNlE4KM7:TR?=	NGLIcXRUSU6JRWK=
NCI-H2405	NGDoe2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHJZ3hsUUN3ME2xNk4zODN4IN88US=>	MV\TRW5ITVJ?
KGN	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3:xSGlEPTB;MUKuNlkxOSEQvF2=	Mn\QV2FPT0WU
BB49-HNC	NHGzNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn61TWM2OD1zMj6zPVU3KM7:TR?=	NFHJ[lRUSU6JRWK=
NCI-H1693	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2C3N2lEPTB;MUKuOVgyPiEQvF2=	NUPWNIR1W0GQR1XS
RO82-W-1	NVP1O3NiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTF\|LkC2OFkh\|ryP	NWm0THdoW0GQR1XS
CAL-85-1	M4fyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTITJU{UUN3ME2xN{41Ozl7IN88US=>	NUL3XVRLW0GQR1XS
H-EMC-SS	Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPKTWM2OD1zMz65NVA1KM7:TR?=	MmDRV2FPT0WU
SW1783	M{f5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFWzN\|RKSzVyPUG0MlI{QTFizszN	MXzTRW5ITVJ?
LB771-HNC	NF;NV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDETWM2OD1zND60NVkh\|ryP	MUjTRW5ITVJ?
HCC70	MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIO3OplKSzVyPUG0MlQzOzNizszN	M13rOXNCVkeHUh?=
KNS-81-FD	M1;yWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTF2LkewOFUh\|ryP	MXnTRW5ITVJ?
KYSE-520	M{TLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPSR3JZUUN3ME2xOE46OjdizszN	M13ETHNCVkeHUh?=
TGBC24TKB	NIe2TndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2j6[2lEPTB;MUSuPVU{QSEQvF2=	Mn;MV2FPT0WU
SNB75	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PTVGlEPTB;MUWuNFczQSEQvF2=	NEjkOWhUSU6JRWK=
SW872	NFjR[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTF3LkKyNVgh\|ryP	NIHUNGpUSU6JRWK=
U031	NXj6bGhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfqSIF{UUN3ME2xOU45ODJ6IN88US=>	MVnTRW5ITVJ?
ChaGo-K-1	NIHrSmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PZfmlEPTB;MUWuPFM2QSEQvF2=	NIPDPW1USU6JRWK=
NCI-H441	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PLU2lEPTB;MU[uNFA{QSEQvF2=	M1z6XHNCVkeHUh?=
TE-12	M4LURmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWi3N\|B5UUN3ME2xOk4yQDd\|IN88US=>	NXfVXFJwW0GQR1XS
NCI-H1755	M{XlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTUTWM2OD1zNj61O\|Mh\|ryP	M17HNnNCVkeHUh?=
KNS-42	NVvzVXM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4W4e2lEPTB;MU[uOlU5QSEQvF2=	MlXxV2FPT0WU
SK-PN-DW	NUPNVHhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHPRpZmUUN3ME2xO{41OjBzIN88US=>	NUDGOlM2W0GQR1XS
NCI-H226	NHXjWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHJRnJKSzVyPUG3Mlk{PDVizszN	MoDaV2FPT0WU
K-562	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fxWWlEPTB;MUiuOlMyPyEQvF2=	NYHOZpR5W0GQR1XS
A388	MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoO0TWM2OD1zOT6wN\|A{KM7:TR?=	MkHSV2FPT0WU
ZR-75-30	NYTS[3ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTiWow6UUN3ME2xPU4xQTZ6IN88US=>	NEnWSGFUSU6JRWK=
LU-135	MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTF7LkK2N\|Yh\|ryP	M3zPdXNCVkeHUh?=
NCI-H2029	MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTF7Lk[wNlEh\|ryP	MYPTRW5ITVJ?
HT-1197	MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTDXZFKSzVyPUG5MlkzOjdizszN	NIHoN3lUSU6JRWK=
IGR-1	NGjpd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPNTWM2OD1{MD6zNVE4KM7:TR?=	MWHTRW5ITVJ?
U-87-MG	NHLQXWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDQUXpRUUN3ME2yNE43PDF\|IN88US=>	MljPV2FPT0WU
NCI-H1304	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTJyLke1NFEh\|ryP	NWrJfY1vW0GQR1XS
RCC10RGB	Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTJzLkK4Nlkh\|ryP	MmPVV2FPT0WU
NCI-H520	NWnURZV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\STWM2OD1{Mj63OlEyKM7:TR?=	M{O4O3NCVkeHUh?=
SK-LU-1	M37vWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV:zcWhnUUN3ME2yN{4xPzF6IN88US=>	NEfBbmxUSU6JRWK=
UACC-893	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPxTWM2OD1{Mz6xNFM5KM7:TR?=	NES4VVhUSU6JRWK=
NCI-H2347	NGTKbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkSyTWM2OD1{Mz6yOlc1KM7:TR?=	NWK1V5JIW0GQR1XS
U-118-MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTJ\|LkeyNVch\|ryP	NEPz[HZUSU6JRWK=
NCI-H596	M1PpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmP5TWM2OD1{Mz65NFU2KM7:TR?=	MX\TRW5ITVJ?
MZ1-PC	M4LSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorsTWM2OD1{ND62O\|U6KM7:TR?=	NHXjZ5NUSU6JRWK=
SW1417	M3jU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn36TWM2OD1{NT6yOFk5KM7:TR?=	NIj1PIZUSU6JRWK=
NCI-H82	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7YTWM2OD1{Nj60Nlg5KM7:TR?=	Moi5V2FPT0WU
COLO-678	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTJ5LkS5NVkh\|ryP	M{L2enNCVkeHUh?=
KURAMOCHI	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIf0XXdKSzVyPUK4MlEzPiEQvF2=	NHWyXnlUSU6JRWK=
NCI-H1650	MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTvd4hKSzVyPUOwMlE6OjRizszN	NWPGNItHW0GQR1XS
HCC1954	M3vxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTxTWM2OD1\|MT6zOlY3KM7:TR?=	M332TnNCVkeHUh?=
GAK	NIDI[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTN{LkK2NVYh\|ryP	M2rUbXNCVkeHUh?=
YAPC	Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTtVI5wUUN3ME2zN{44PjR6IN88US=>	M4HjRnNCVkeHUh?=
NCI-H2228	NVrnTWtlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLwTWM2OD1\|ND6zOlA2KM7:TR?=	Ml7VV2FPT0WU
VMRC-RCZ	MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnGboRKSzVyPUO2MlMxOjJizszN	NYTnVIlGW0GQR1XS
NMC-G1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXvUJVKSzVyPUO3MlA2OjlizszN	NYf6VnBlW0GQR1XS
D-336MG	M3LmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\NTWM2OD12MT64OFQzKM7:TR?=	NHq0cYlUSU6JRWK=
UACC-62	NXX5RXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nmNmlEPTB;NEKuOVUxPSEQvF2=	NF[zcGpUSU6JRWK=
C-33-A	NWS3e4RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrpTWM2OD12NT6zNlU3KM7:TR?=	M2exdXNCVkeHUh?=
HCC1937	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLydVBOUUN3ME20O{4yQTV6IN88US=>	NETwPHRUSU6JRWK=
HDLM-2	NWPZPG9PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3X3V2lEPTB;NEeuNlI5PyEQvF2=	MWLTRW5ITVJ?
NCI-H727	M13De2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnCcWRKSzVyPUS3MlI1PTFizszN	NX7BXnVzW0GQR1XS
NY	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTR7LkO5NFgh\|ryP	NHXWN3RUSU6JRWK=
NCI-H2291	M4r4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUS0TVMzUUN3ME20PU45OzBzIN88US=>	MmrsV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-Histone H4 / Ac-Histone H3; PubMed: 21598070 J Neurooncol D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. phospho-CDK1; PubMed: 21598070 Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. phospho-Cdc25c / Cdc25c; PubMed: 21598070 J Neurooncol Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM). Cyclin B1; PubMed: 21598070 J Neurooncol Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h. c-Myc / c-Raf / Akt / Cyclin D1 / CDK4; PubMed: 19440035 Cancer Biol Ther Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control. p-eIF2α / ATF4 / CHOP ; PubMed: 20072656 Neoplasia Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure. p21; PubMed: 21598070 J Neurooncol To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.	21598070 19440035 20072656
Immunofluorescence	HDAC1 / CK19; PubMed: 29917299 Cancer Sci Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment. Nrf2; PubMed: 20566897 Blood Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat. α-SMA; PubMed: 26330748 Mol Vis Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm. Ac-STAT3 / IGF2; PubMed: 27086926 Oncogene Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.	29917299 20566897 26330748 27086926
Growth inhibition assay	Cell apoptosis; PubMed: 19440035 Cancer Biol Ther Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE) Cell viability; PubMed: 27086926 Oncogene The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).	19440035 27086926
ELISA	IGF2; PubMed: 27086926 Oncogene Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. IL-13 / IL-10 / IL-5; PubMed: 18541724 Blood Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM). M-CSF; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF secretion. P < 0.05 and P < 0.001 versus control treatment. MMP-9; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. P < 0.05 and **P < 0.001 versus control treatment.	27086926 18541724 23042302

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	- Collapse Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Formulation: Dissolved in DMSO Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Ethanol	3 mg/mL (11.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03022565	Suspended	Drug: Vorinostat	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	January 2020	Early Phase 1
NCT03167437	Recruiting	Drug: Vorinostat	Crohn''s Disease	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	October 30 2017	Phase 1\|Phase 2
NCT03056495	Recruiting	Drug: N-hydroxy-N''-phenyl-octanediamide (Vorinostat)	Alzheimer Disease	German Center for Neurodegenerative Diseases (DZNE)\|University Hospital Bonn\|University of Göttingen	September 28 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202,Domatinostat) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 267 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 267 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)